



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  A61K 39/00, 39/395, 41/00		A2	(11) International Publication Number: <b>WO 99/65517</b>  (43) International Publication Date: 23 December 1999 (23.12.99)															
<p>(21) International Application Number: PCT/IB99/01114</p> <p>(22) International Filing Date: 15 June 1999 (15.06.99)</p> <p>(30) Priority Data: 09/094,598 15 June 1998 (15.06.98) US 09/152,698 2 September 1998 (02.09.98) US</p> <p>(71) Applicant (for all designated States except US): ALTAREX CORP. [CA/CA]; Campus Tower, Suite 300, 8625-112 Street, Edmonton, Alberta T6G 2E1 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): MADIYALAKAN, Ragupathy [CA/CA]; 9741-89 Avenue, Edmonton, Alberta T6E 2S1 (CA). SCHULTES, Birgit [CA/CA]; 529 Hegler Crescent, Edmonton, Alberta T6R 1T4 (CA). BAUM, Richard, P. [DE/DE]; Bergweg 4, D-55595 Hargesheim (DE). NOUJAIM, Antoine, A. [CA/CA]; 58 Wilkins Road, Edmonton, Alberta T6M 2K4 (CA). LEVEUGLE, Beatrice [CA/CA]; 9741-89 Avenue, Edmonton, Alberta T6E 2S1 (CA). KREUTZ, Fernando, T. [BR/BR]; Apt. 72, Rua Felipe Camarao, 147, CEP-90035-141 Porto Alegre, RS (BR).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>																
<p>(54) Title: THERAPEUTIC COMPOSITIONS THAT PRODUCE AN IMMUNE RESPONSE BY ALTERING THE ANTIGEN</p> <table border="1"> <thead> <tr> <th>Inhibitor</th> <th>Black Segment (%)</th> <th>White Segment (%)</th> </tr> </thead> <tbody> <tr> <td>CA125</td> <td>26</td> <td>2</td> </tr> <tr> <td>B43.13 scFv</td> <td>22</td> <td>6</td> </tr> <tr> <td>B27.1 F(ab')</td> <td>11</td> <td>17</td> </tr> <tr> <td>M11 F(ab')</td> <td>8</td> <td>11</td> </tr> </tbody> </table>				Inhibitor	Black Segment (%)	White Segment (%)	CA125	26	2	B43.13 scFv	22	6	B27.1 F(ab')	11	17	M11 F(ab')	8	11
Inhibitor	Black Segment (%)	White Segment (%)																
CA125	26	2																
B43.13 scFv	22	6																
B27.1 F(ab')	11	17																
M11 F(ab')	8	11																
<p>(57) Abstract</p> <p>The invention concerns methods and compositions for stimulating a host's immune response, particularly for the treatment of cancer. The methods and compositions according to the invention use binding agents such as antibodies to generate an immune response to a predetermined soluble antigen. In accordance with the invention, the binding agent-soluble antigen complex alters the immunogenic condition of the host by generating new immunogens that are recognizable by the immune system. This leads to a humoral and/or cellular immune response.</p>																		

BEST AVAILABLE COPY

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

1

## THERAPEUTIC COMPOSITIONS THAT PRODUCE AN IMMUNE RESPONSE BY ALTERING THE ANTIGEN

5

Technical Field

The invention concerns methods and compositions having increased therapeutic effect by altering the immunogenicity of the active component without decreasing the active component's antigenicity. Typically, a beneficial therapeutic effect is derived from altering the state of the immune system, and for some embodiments of the invention, e.g., cancer immunotherapy, immunogenicity is induced, activated, or increased. The invention also concerns methods and compositions for stimulating a host's immune response, particularly for the treatment of cancer. The methods and compositions according to the invention use binding agents such as antibodies to generate an immune response to a pre-determined antigen.

17

Background Art

In vertebrates, the mechanisms of natural and specific immunity cooperate within a system of host defenses, the immune system, to eliminate foreign invaders. The hypothesis that the immune system ought to be able to recognize tumors and thus could be recruited in the fight against cancer has been a driving force behind outstanding efforts of many immunologists. This approach is attractive because of the unique ability of the immune system to specifically destroy affected cells while mostly sparing normal tissue. Moreover, the initial immune response is known to leave behind a long-term memory that serves to protect from the same disease in the future. No drug treatment for cancer can claim such specificity or memory.

25

An immunotherapeutic strategy for the treatment of cancer and other diseases or conditions involve one or more components of the immune system to trigger a complex cascade of biological reactions focused on eliminating a foreign molecule from the host. Vertebrates have two broad classes of immune responses: antibody responses, or humoral immunity, and cell-mediated immune responses, or cellular immunity.

1           Humoral immunity is provided by B lymphocytes, which, after proliferation  
and differentiation, produce antibodies (proteins also known as immunoglobulins) that  
circulate in the blood and lymphatic fluid. These antibodies specifically bind to the  
antigen that induced them. Binding by antibody inactivates the foreign substance, e.g.,  
5           a virus, by blocking the substance's ability to bind to receptors on a target cell or by  
attracting complement or the killer cells that attack the virus. The humoral response  
primarily defends against the extracellular phases of bacterial and viral infections. In  
humoral immunity, serum alone can transfer the response, and the effectors of the  
9           response are protein molecules, typically soluble, called antibodies. Lymphocytes  
produce these antibodies and thereby determine the specificity of immunity; it is this  
response that orchestrates the effector limbs of the immune system. Cells and proteins,  
such as antibodies, that interact with lymphocytes play critical roles in both the  
13           presentation of antigen and in the mediation of immunologic functions.

17           Individual lymphocytes respond to a limited set of structurally related antigens.  
As noted in more detail below, this function is defined structurally by the presence of  
receptors on the lymphocyte's surface membrane that are specific for binding sites  
(determinants or epitopes) on the antigen.

21           Lymphocytes differ from each other not only in the specificity of their  
receptors, but also in their functions. One class of lymphocytes, B cells, are precursors  
of antibody-secreting cells, and function as mediators of the humoral immune response.

25           Another class of lymphocytes, T cells, express important regulatory functions,  
and are mediators of the cellular immune response. The second class of immune  
responses, cellular immunity, involve the production of specialized cells, e.g., T  
lymphocytes, that react with foreign antigens on the surface of other host cells. The  
cellular immune response is particularly effective against fungi, parasites, intracellular  
viral infections, cancer cells and other foreign matter. In fact, the majority of T  
lymphocytes play a regulatory role in immunity, acting either to enhance or suppress  
the responses of other white blood cells. These cells, called helper T cells and  
29           suppressor T cells, respectively, are collectively referred to as regulatory cells. Other T  
lymphocytes, called cytotoxic T cells, kill, for example, virus-infected cells or tumor

1 cells. Both cytotoxic T cells and B lymphocytes are involved directly in defense against  
infection and are collectively referred to as effector cells. There are a number of  
intercellular signals important to T cell activation. Under normal circumstances an  
antigen degrades or is cleaved to form antigen fragments or peptides. Presentation of  
5 antigen fragments to T-cells is the principal function of MHC molecules, and the cells  
that carry out this function are called antigen-presenting cells (APC: including but not  
limited to dendritic cells, macrophages, and B cells).

9 The time course of an immune response is subdivided into the cognitive or  
recognition phase, during which specific lymphocytes recognize the foreign antigen; the  
activation phase, during which specific lymphocytes respond to the foreign antigen; and  
the effector phase, during which antigen-activated lymphocytes mediate the processes  
required to eliminate the antigen-carrying target cells. Lymphocytes are immune cells  
13 that are specialized in mediating and directing specific immune responses. T cells and B  
cells become morphologically distinct only after they have been stimulated by an  
antigen.

17 The capture and processing of an antigen by APCs is essential for the induction  
of a specific immune response. APCs capture antigens via specific receptors, such as Fc  
receptors or mannose receptors, or the APCs non-specifically phagocytose antigen. The  
capture through specific receptors is more efficient; antigens can be presented better  
when in complex with, for example, an antibody. Such a complex can be formed by  
21 injecting an antibody to a circulating antigen (e.g., PSA or CA 125), and the immune  
complexes can be targeted to dendritic cells and macrophages through the Fc-receptors  
present on these cells. However the high number of Fc receptors on neutrophils may  
considerably limit this process.

25 Immunotherapy is based on the principle of inducing or activating the immune  
system to recognize and eliminate undesirable cells, such as neoplastic cells. The key  
elements in any immunotherapy is to induce or trigger the host immune system to first  
recognize a molecule as an unwanted target, and then to induce the system to initiate a  
29 response against that molecule. In healthy hosts, the immune system recognizes surface  
features of a molecule that is not a normal constituent of the host (i.e., is "foreign" to

1 the host). Once the recognition function occurs, the host must then direct a response  
against that particular foreign molecule.

5 Both the recognition and the response elements of the immune system involve a  
highly complex cascade of biological reactions. In most immunologically based  
disorders, at least one of the steps in the recognition phase, or at least one of the steps in  
the response phase, are disrupted. Virtually any disruption in either of these complex  
pathways leads to a reduced response or to the lack of any response. The inability of  
the immune system to destroy a growing tumor has been attributed, among other  
9 factors, to the presence of tumor-associated antigens (TAA) that induce immunological  
tolerance and/or immunosuppression. For example, in some kinds of cancer, the cancer  
itself tricks the host into accepting the foreign cancer cell as a normal constituent, thus  
disrupting the recognition phase of the immune system. The immunological approach  
13 to cancer therapy involves modification of the host-tumor relationship so that the  
immune system is induced or amplifies its response to the TAAs. If successful, inducing  
or amplifying the immune system can lead to tumor regression, tumor rejection, and  
occasionally, to tumor cure.

17

#### Antigenicity and Immunogenicity

21 As used herein, if a binding agent can recognize an antigen, i.e., can bind to or  
interact with an antigen, then the antigen is said to be antigenic. If the immune system  
can also mount an active response against the antigen, a complex containing the antigen,  
a portion of the complex, or the binding agent itself, it is said to be immunogenic.

25 The conventional definition of an antigen is a substance (such as an antibody or  
an antigen) that can elicit in a vertebrate host the formation of a specific antibody or the  
generation of a specific population of lymphocytes reactive with the substance. As  
frequently occurs in science, however, it is now known that this definition, although  
accurate, is not complete. For example, it is now known that some disease conditions  
suppress or inactivate the host immune response, and the substance that would have  
been expected to elicit an antibody or generate specific lymphocytes, does not. Thus,  
29 not all antigens are capable of eliciting a human immune response.

1       Typically, the antibody's capability of binding the antigen is based on highly  
complementary structures. That is, the shape of the antibody must contain structures  
that are the compliment of the structures on the antigen. The portion of the antigen to  
which an antibody binds is called the "antigenic determinant", or "epitope". Thus  
5       antigens are molecules that bear one or more epitopes which may be recognized by  
specific receptors in an immune system, a property called antigenicity.

9       Immunogenicity refers to the property of stimulating the immune system to  
generate a specific response. Thus, all immunogens are antigens, but not vice-versa.  
Although an immune system may recognize an antigen (e.g., binds to a T or B cell  
receptor), it does not respond to the antigen unless the antigen or an antigen-containing  
complex is also immunogenic.

13      An immune response to a particular antigen is greatly influenced by the  
structure and activity of the antigen itself, as well as myriad other factors. In some  
cases, the immune system is not able to generate an immune response to a particular  
antigen, a condition that is called tolerance.

17      In influencing whether an antigen is immunogenic or immunotolerant, an  
important characteristic of the antigen is the degree of difference between the antigen  
and similar molecules within the host. The most immunogenic antigens are those that  
have no homologs in the host, i.e., those that are most "foreign." Other factors that  
promote immunogenicity include higher molecular weight, greater molecular  
21      complexity, the proper antigen dose range, the route of administration, the age of the  
host, and the genetic composition of the host (including exposure to antigens during  
fetal development).

25      As noted above, antigens may have one or more epitopes or binding sites that  
are recognized by specific receptors of the immune system. Epitopes may be formed by  
the primary structure of a molecule (called a sequential epitope), or may be formed by  
portions of the molecule separate from the primary structure that juxtapose in the  
secondary or tertiary structure of the molecule (called a conformational epitope). Some  
29      epitopes, e.g., cryptic epitopes, are hidden in the three dimensional structure of the  
native antigen, and become immunogenic only after a conformational change in the

1 antigen provides access to the epitope by the specific receptors of the immune system. Some antigens, e.g., tumor-associated antigens such as ovarian cancer or breast cancer antigens, have multiple antibody binding sites. These antigens are termed "multi-epitopic" antigens.

5 An important feature and function of a comprehensive therapeutic reagent is the ability to initiate recognition and response to an antigen, to induce a cellular and humoral response (either or both) to the antigen, and to increase the immunogenicity of a molecule without affecting its antigenicity.

9 Antibodies bear three major categories of antigen-specific determinants – isotypic, allotypic, and idiosyncratic – each of which is defined by its location on the antibody molecule. For the purpose of the present invention, we shall only focus on the idiosyncratic category.

13 Idiosyncratic determinants, or idiosyncopes, are markers for the V region of an antibody, a relatively large region that may include several idioscopes each capable of interacting with a different antibody. The set of idioscopes expressed on a single antibody V region constitutes the antibody idiosyncracy. An antibody (Ab1) whose antigen combining site (paratope) interacts with an antigenic determinant on another antibody V region (idioscope) is called an anti-idiosyncratic antibody (Ab2). Thus, an Ab2 antibody includes an antigen binding site which is also an antibody binding site. A portion of such anti-idiosyncratic antibodies (i.e., Ab2 $\beta$ ) will identify an epitope within the paratope of the idiosyncracy antibody, thus presenting an "internal" image of the epitope identified by the idiosyncracy antibody on the tumor associated antigen. The phenomenon of producing an anti-idiosyncratic antibody having the internal image of the antigen may permit the use of antibodies to replace the antigen as an immunogen. For a graphic representation of these types of antibodies and their interaction, see Figure 1.

21

25

For tumors that have antigens, there are at least four theories why the immune response may fail to destroy a tumor: 1) there are no B cells or cytotoxic T lymphocytes (CTL) capable of recognizing the tumor; 2) there are no TH cells capable of recognizing the tumor; 3) TS cells become activated before TH cells, thus preventing

1 B-cell and CTL activation; and 4) the genes regulating tumor proliferation may be  
present from birth, so the host does not treat the gene products as "foreign."

5 "Passive immunotherapy" involves the administration of antibodies to a patient.  
Antibody therapy is conventionally characterized as passive since the patient is not the  
source of the antibodies. However, the term passive is misleading because the patient  
can produce anti-idiotypic secondary antibodies which in turn can provoke an immune  
response which is cross-reactive with the original antigen. "Active immunotherapy" is  
the administration of an antigen, in the form of a vaccine, to a patient, so as to elicit a  
9 protective immune response. Genetically modified tumor cell vaccines transfected with  
genes expressing cytokines and co-stimulatory molecules have also been used to alleviate  
the inadequacy of the tumor specific immune response.

13 If a specific antibody from one animal is injected as an immunogen into a  
suitable second animal, the injected antibody will elicit an immune response (e.g.,  
produce antibodies against the injected antibodies -- "anti-antibodies"). Some of these  
anti-antibodies will be specific for the unique epitopes (idiotypes) of the variable domain  
of the injected antibodies (anti-idiotypic antibodies). Others will be specific for the  
17 epitopes of the constant domains of the injected antibodies and hence are known as anti-  
isotypic antibodies.

21 The various interactions based on idiotypic determinants, called the idiotypic  
network, is based on the immunogenicity of the variable regions of immunoglobulin  
molecules (Ab1) which stimulate the immune system to generate anti-idiotypic  
antibodies (Ab2), some of which mimic antigenic epitopes ("internal image") of the  
original antigen. The presence of internal image antibodies (Ab2 $\beta$ ) in the circulation can  
in turn induce the production of anti-anti-idiotypic antibodies (Ab3), some of which  
25 include structures that react with the original antigen.

29 The "network" theory states that antibodies produced initially during an  
immune response will carry unique new epitopes to which the organism is not tolerant,  
and therefore will elicit production of secondary antibodies (Ab2) directed against the  
idiotypes of the primary antibodies (Ab1). These secondary antibodies likewise will  
have an idiotype which will induce production of tertiary antibodies (Ab3) and so forth.

1

**Ab1 → Ab2 → Ab3**

In other words, an anti-idiotypic antibody may be a surrogate antigen.

5 Two therapeutic applications arose from the network theory: 1) administer Ab1 which acts as an antigen inducing Ab2 production by the host; and 2) administer Ab2 which functionally imitates the tumor antigen.

9 The development of the "network" theory led investigators to suggest the direct administration of exogenously produced anti-idiotype antibodies, that is, antibodies raised against the idiotype of an anti-tumor antibody. Such an approach is disclosed in U.S. Patent 5,053,224 (Koprowski, et al.) Koprowski assumes that the patient's body will produce anti-antibodies that will not only recognize these anti-idiotype antibodies, but also the original tumor epitope.

13 Conventional anti-idiotype antibodies are made by intraspecies or interspecies immunization with a purified antigen-specific pool of antibodies or a monoclonal antibody. The resulting antiserum is then extensively absorbed against similar molecules with the same constant region to remove antibodies with anti-C<sub>H</sub>C<sub>L</sub> specificities. See, for example, Briles, et al.; "Idiotypic Antibodies," *Immunochemical Techniques* (New York, Academic; Colowich and Kaplan, eds; 1985). The production of anti-ID antibodies against self-idiotopes was one of the first key predictions of the network theory [Rodkey, S., *J. Exp. Med.* 130:712-719 (1974)].

21 A human anti-idiotypic monoclonal antibody (Ab2) has been shown to induce anti-tumor cellular responses in animals and appears to prolong survival in patients with metastatic colorectal cancer. See Durrant, L.G. et al., "Enhanced Cell-Mediated Tumor Killing in Patients Immunized with Human Monoclonal Anti-Idiotypic Antibody 105AD7," *Cancer Research*, 54:4837-4840 (1994). The use of anti-idiotypic antibodies (Ab2) for immunotherapy of cancer is also reviewed by Bhattacharya-Chatterje, et al; *Cancer Immunol. Immunother.* 38:75-82 (1994).

29 Idiotopes on lymphoid receptors may in some cases mimic external antigens because of the extensive diversity of the immune system. This idea prompted many attempts to use the internal image of a foreign antigen, mimicked by the idiotypes of T

1 or B receptors, to act as targets for anti-idiotypic antibodies. In this way, it has been  
proposed that anti-idiotypic antibodies may induce populations of T or B cells that can  
bind the extrinsic (or soluble) antigen. Such anti-idiotypic antibodies can be used as  
vaccines, many of which are summarized in Greenspan, NS, and Bona, CA; *The FASEB  
Journal*, 7:437-444 (1992).

5 The ability to up- or down-regulate immune responses and to control potentially  
auto-reactive immunocompetent cells is vital for normal immune function and survival.  
Regulatory mechanisms include the induction of clonal anergy (via inappropriate  
9 antigen-presenting cells), peripheral clonal deletion/apoptosis, cytokine (e.g.  
transforming growth factor-beta (TGF- $\beta$ ) or IL-10)-induced non-responsiveness, 'veto'  
cells, auto-reactive cytolytic T cells, and both non-specific and antigen-specific T  
suppressor cells. At least in theory, each of these regulatory systems provides a  
13 mechanistic basis for 'therapeutic intervention'.

In addition to cancer immunotherapy, control of abnormal acute and chronic  
inflammatory response is also one of the most important challenges in medicine.  
Typical examples of acute and chronic inflammation include atopy, urticaria, asthma,  
17 autoimmune hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus,  
granulomatous diseases, tuberculosis, and leprosy.

Like the tumor immune response described above, the aim of the inflammatory  
response is the elimination of harmful agents. Further, the treatment of autoimmune  
21 inflammatory disease is sometimes complicated by autoimmune factors that prevent the  
host from eliminating the harmful agents, thereby leading to a persistent or chronic  
inflammatory response or condition.

Presently, it has been determined that essential events in the development of  
25 inflammation includes a cellular response involving neutrophils and macrophages,  
specifically the rolling, activation, and adhesion of neutrophils to endothelium via  
selectins-carbohydrate ligand interaction ( and may include neutrophil extravasation).

Therapeutic compositions for the treatment of inflammation have included  
29 agents that bind to one or more of the mediators of inflammation. For example,  
antibodies specific for selectin carbohydrate ligands, and inhibiting selectin-

1 carbohydrate ligand binding, may be important anti-inflammatory targets for the  
development of therapeutic compositions for the treatment of inflammation.

5 In addition to the above, there are other cases where an anti-idiotypic mode of induction of a response may be useful. If a given epitope of a protein is discontinuous  
and results from three-dimensional folding, an anti-Id can be produced that would  
mimic that structure. Further, in immunizing against latent and/or immunosuppressive  
viruses, there is the possibility of well known deleterious effects not solvable by the use  
of attenuated viruses (e.g., mumps, measles, rubella, and HIV). The use of anti-ID  
9 induction of protective immunity may avoid these deleterious effects.

#### Summary of the Invention

13 The present invention is a method and composition for generating both a humoral and/or a cellular immune response by administering a binding agent that specifically binds to a pre-selected soluble antigen. In accordance with the invention, the binding agent-soluble antigen complex alters the immunogenic condition of the host by generating new immunogens that are recognizable by the immune system. This  
17 leads to a humoral and/or a cellular response. In one embodiment of the invention, the immune response comprises an anti-tumor response and/or cell killing.

21 The present invention is a comprehensive method for the treatment of certain diseases and conditions that includes, but is not limited to, targeting a pre-determined antigen, preferably a multi-epitopic antigen and/or preferably soluble; administering a binding agent, preferably a monoclonal antibody, and inducing a comprehensive immune response against the disease or condition that generated the target antigen. In a preferred embodiment of the invention, the binding agent or the binding agent/antigen  
25 complex induces the production of a humoral response, as evidenced in part by the production of anti-antigen (e.g., anti-tumor or anti-inflammation) antibodies, Ab3 and/or Ab1c; and/or induces the production of a cellular response, as evidenced in part by the production of T-cells that are specific for the binding agent, the binding agent/antigen complex, and/or the antigen.

29 The present invention also includes methods and compositions for altering the

1 immunogenic state of the host organism. In altering the immunogenic state, the  
compositions and methods of the present invention increase, decrease, or maintain the  
host's immunogenic state. An example of deriving a therapeutic benefit by increasing  
the immunogenicity includes but is not limited to treatments for cancer or some  
5 infectious diseases, such as hepatitis. An example of decreasing the immunogenicity  
includes but is not limited to treatments for rheumatoid arthritis. An example of  
maintaining immunogenicity includes but is not limited to supplemental treatments for  
patients that have become tolerant to antigens after an initial response. In a most  
9 preferred embodiment of the invention, the methods and compositions do not decrease  
the antigenicity of the active component in the therapeutic composition.

13 The present invention also includes methods and compositions for increasing the  
over-all host response to a disease or condition. These methods and compositions  
produce a therapeutic benefit for the recipient.

17 The present invention also is a therapeutic composition comprising an active  
agent, or binding agent, that specifically binds to a pre-determined soluble antigen,  
wherein the binding agent, upon binding to the antigen, forms a complex that is both  
antigenic and immunogenic.

The compositions and methods of the present invention may also include one or  
more steps or substances that increase the over-all immunogenicity.

21 The therapeutic compositions and methods of the present invention are suitable  
for the treatment of any disease or cancer that produces a soluble antigen, preferably a  
multi-epitopic antigen.

25 The present invention also includes a method for designing new therapeutic  
agents comprising selecting a soluble antigen, preferably an antigen that has been  
determined to be multi-epitopic; and selecting a binding agent that specifically binds to  
said antigen to form a complex. In accordance with the invention, the binding agent,  
the binding agent/antigen complex, and/or the antigen lead to the production of a  
humoral and/or cellular response *in vivo*. In a preferred embodiment of the  
29 invention, the method for designing a new therapeutic agent results in a binding agent  
or the binding agent/antigen complex that induces the production of a humoral

1 response, as evidenced in part by the production of anti-tumor or anti-inflammation  
antibodies, Ab3 and/or Ab1c; and/or induces the production of a cellular response, as  
evidenced in part by the production of T-cells that are specific for the binding agent, the  
binding agent/antigen complex, and/or the antigen.

5 Although several investigators have shown that antigen-specific antibodies can  
enhance the immune response to those antigens presented in a complex form, the  
present invention is the first to demonstrate that the injection of an antibody against a  
single epitope can induce a multi-epitopic immune response in cancer patients, provided  
9 that the patients' sera contained the respective antigen. The present invention also  
demonstrates that this antibody injection can change the patient's immune response in  
such a way that the self-protein CA125 can now be recognized by the immune system.

Stimulation of T cells reactive with subdominant or cryptic epitopes of self-  
13 proteins has been suggested as an important factor in inducing immunity to a pre-  
determined antigen, e.g., an antigen involved in a disease or condition such as cancer or  
auto-immunity. Antibody-enhanced or -altered presentation of an antigen, such as  
CA125, in an antibody complex, e.g., bound to MAb-B43.13, by B cells (antibody-  
17 specific), or macrophages or dendritic cells (both F<sub>c</sub> receptor mediated ), may result in  
presentation of different peptides to the immune system than those obtained by  
presentation of the antigen alone. This can lead to sufficient presence of antigen-specific  
peptides from subdominant or cryptic epitopes which may in turn stimulate low-  
21 affinity T cells that escaped clonal deletion in the thymus or re-stimulate T cells which  
were suppressed. The immune response induced by exogenous administration of an  
antibody to a circulating self-antigen can therefore be compared to that observed in  
auto-immune diseases. This may also explain why presence of immune complexes of  
25 antigen with autologous human antibodies is often not correlated with improved  
survival. Human B cells recognize preferably immune-dominant epitopes of the  
antigen, leading to presentation of epitopes against which T cells were formed during  
fetal development. Murine antibodies on the other hand, recognize immune-dominant  
29 epitopes in mice which are not necessarily equivalent to the human immune-dominant  
epitopes.

1        The capture and processing of an antigen, e.g., PSA, by B-cells may also occur  
through the interaction of the membrane bound Ab2 with the anti-antigen/antigen  
(e.g., anti-PSA/PSA) complexes and in a similar manner through the interaction of  
membrane bound Ab3 with the antigen (complexed or not with the anti-PSA antibody).

5        Although applicants do not wish to be bound by any particular theory of  
operability, it is believed that the observed immunological response achieved by the  
present invention is attributable to an interaction between a newly formed antigen and  
the human patient's immune system. As noted above, a portion of the immune  
9        response includes inducing the production of anti-(anti-idiotype) antibodies by the  
patient. Within this set of anti-(anti-idiotype) antibodies are those that are directly  
complimentary to the paratope of an anti-idiotype antibody. It is further believed that  
the paratope of the anti-idiotype antibody presents an "internal" image of the tumor  
13        cell epitope identified (i.e., selectively bound) by the idiotype antibody and, therefore,  
the anti-(anti-idiotype) antibodies will also bind the tumor antigen. In effect, the present  
method induces a immunological response to the first antigen, e.g., a tumor antigen, by  
presenting a second antigen (the paratope of the anti-idiotype antibody, which shares  
17        homologies with the tumor antigen) to a portion of the patient's resulting antibodies.

21        The present invention concerns altering immunogenicity in a manner that  
produces a beneficial or therapeutically desirable effect. As used herein, a beneficial or  
desirable immune response is one that produces a therapeutically desirable result. A  
beneficial therapeutic response will typically include activation of the immune system  
and/or one or more of its components, induction of the immune system and/or one or  
more of its components, and/or a T cell immune response, and/or a humoral immune  
response. For example, for a cancer such as ovarian cancer, a beneficial or desirable  
25        immune response includes the production of an antibody that immunoreacts with a  
previously non-immunoreactive ovarian cancer antigen. In this example, the immune  
response to an antigen is increased. In another example, for a condition such as  
inflammation, a beneficial or desirable immune response includes the production of an  
29        antibody that immunoreacts with a previously immunoreactive antigen so that it  
becomes non-immunoreactive. In this example, the immune response is decreased. In

1 transplantation, the immune system attacks MHC-disparate donor tissue leading to graft  
rejection, in autoimmune disease it attacks normal tissues, and in allergy the immune  
system is hyper-responsive to otherwise harmless environmental antigens. It is now  
recognized that immunosuppressive therapy may be appropriate for treating each of  
5 these disorders.

#### Description of the Figures

9 Figure 1 is a graphic representation of the different types of antibodies and their  
structural relationship to each other and to an antigen.

Figure 2 shows the production of Ab2 in response to the administration of a  
composition of the invention.

13 Figure 3 shows the production of B cells in response to the administration of a  
composition of the invention. Legend: open bars, 0.1  $\mu$ g or kU per mL; hatched bars, 1  
 $\mu$ g or kU per mL; closed bars, 10  $\mu$ g or kU per mL.

17 Figure 4 shows that a binding agent/antigen complex stimulates an immune  
response. Legend: open bars, 0.1  $\mu$ g or kU per mL; hatched bars, 1  $\mu$ g or kU per mL;  
closed bars, 10  $\mu$ g or kU per mL.

Figure 5 shows the ability of a composition of the invention to increase the  
immunogenicity of its target antigen. Legend: •, MAb 43.13; ■, MAb 43.13 + CA 125;  
▲, CA 125.

21 Figure 6 shows the characterization of anti-CA 125 antibodies from patients  
injected with MAb B43.13. Anti-CA 125 positive samples were tested for inhibition of  
their binding to CA 125 (solid phase) by CA 125, MAb-B43.13 scFv, MAb-B27.1 F(ab'),  
or MAb M11 F(ab'). Single chain MAb-B43.13, F(ab') MAb-B27.1, and F(ab') M11 were  
25 used in the inhibition studies to avoid non-specific inhibition of the Fc portion of the  
antibody and cross-reactivity due to HAMA. To be considered to be significant,  
inhibition had to be at least 15%

#### 29 Disclosure of the Invention

The present invention comprises a method and composition for altering

1 immunogenicity resulting in the induction or mediation of a comprehensive immune response.

5 The present invention comprises a method for increasing the immunogenicity of an administered composition by target selection, by activation methodologies, and by delivery systems that, in combination, induces either cellular or humoral immunity, or both.

9 The present invention involves the discovery that binding a binding agent to a pre-determined antigen, such as a multi-epitopic tumor-associated antigen, increases the immunogenicity of the immunogen while maintaining its antigenicity, and leads to the generation of a humoral and/or cellular response to the immunogen. The methods and compositions of the present invention typically mediate a host's ability to generate an immune response to a previously non-immunogenic antigen. In this manner, the host 13 immune system can recognize and initiate an immune response to the previously unrecognized antigen.

17 In preferred embodiments of the invention, the binding agent is a non-labeled binding agent, even more preferably, a monoclonal antibody. The pre-determined antigen, defined in more detail below, is any immunotolerant antigen, preferably a tumor associated antigen.

21 A composition and method of the present invention includes administering a binding agent that specifically binds to a pre-determined antigen to form a complex, wherein the complex is immunogenic. In preferred embodiments of the invention, the immunogenicity is evident in the production and/or induction of anti-idiotype antibodies (Ab2), anti-anti-antibodies (Ab3), antibodies to the complex, antibodies to the antigen (Ab1c, which is used interchangeably with Ab3'), cytotoxic lymphocytes, such 25 as killer T cells or natural killer (NK) cells, and/or T cell proliferation.

29 A composition and method of the present invention includes administering an effective amount of a binding agent that specifically binds to a pre-determined antigen, wherein the antigen is present in vivo in a high amount, allowing the binding agent to bind to the antigen, and inducing the production of a beneficial immune response against the antigen.

1 The present invention also includes compositions and methods that result in the induction of a beneficial immune response, particularly where one skilled in the art would not expect to find an antigen-specific immune response, e.g., tumor-associated antigens ("self") antigens.

5 An additional composition of the present invention may also include a modified antigen, wherein a soluble, preferably multi-epitopic, antigen is modified by binding to a binding agent. An additional method of the present invention may include producing the modified antigen, and/or using the modified antigen to achieve a therapeutic effect, 9 e.g., producing, inducing, or inhibiting an immune response against the antigen.

13 In one embodiment of the invention, the methods and compositions include all binding agents as defined herein, exclusive of B43.13 antibodies. For example, a method and composition of the invention may include a composition comprising a binding agent that is free of, or substantially free of, B43.13 antibodies.

17 The invention further includes methods and compositions for treating ovarian cancer comprising a binding agent that specifically binds to an ovarian cancer antigen, such as CA 125, wherein said binding agent is exclusive of B43.13 antibodies, wherein the complex between the binding agent and the antigen is immunogenic.

21 In certain embodiments the invention provides a method for inducing a host immune response against a multi-epitopic *in vivo* antigen, other than a tumor associated antigen, present in the host's serum, which antigen preferably does not elicit a host immune response, the method comprising contacting the antigen with a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair wherein a host immune response is elicited against a second epitope on the antigen.

25 In certain embodiments the invention provides a method for inducing the production of an immune response against a multi-epitopic *in vivo* tumor associated antigen, other than a CA125, CA19.9 and CA15.3, present in a host's serum, which antigen does not elicit a host immune response, the method comprising contacting the antigen with a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen

1 pair wherein a host immune response is elicited against a second epitope on the antigen.

5 In certain embodiments the invention provides a method for inducing an immune response against a cellular antigen that does not elicit a host immune response, the method comprising administering to the host a binding agent that binds an epitope of a soluble form of the antigen in an amount of binding agent between 0.1 $\mu$ g and 2 mg per kg of body weight of the host.

9 In certain embodiments, the invention provides a method comprising intravenously administering to the host a binding agent that binds an epitope of a soluble form of a cellular antigen.

13 In certain embodiments the host immune response comprises a cellular and humoral immune response. In certain embodiments, the host immune response comprises a cellular response. In certain embodiments, the host immune response comprises a humoral response. In certain embodiments, the antigen is a soluble antigen. In certain embodiments the binding agent is an antibody. In certain embodiments, the antibody is a murine monoclonal antibody. In certain embodiments the antibody does not induce isotypic induced HAMA toxicity in the host. In certain embodiments the antigen is associated with a human disease or pathological condition. In certain embodiments the disease or pathological condition is cancer. In certain embodiments the binding agent is photoactivated. In certain embodiments the humoral response comprises anti-idiotype antibodies. In certain embodiments, the amount of binding agent is at least 1  $\mu$ g and less than 2 mg, preferably between 1 $\mu$ g and 200  $\mu$ g per kg of body weight of the host.

17 Those skilled in the art will recognize that these embodiments may be used alone, or in any combination.

25 In certain embodiments, the invention provides a therapeutic composition comprising a binding agent specific for a first epitope on a multi-epitopic *in vivo* antigen, other than a tumor associated antigen, present in the host's serum, which antigen preferably does not elicit a host immune response, wherein the binding agent specifically binds to a first epitope on the antigen and forms a binding agent/antigen pair wherein a host immune response is elicited against a second epitope on the antigen.

1        In certain embodiments the invention provides a therapeutic composition comprising a binding agent specific for a first epitope on a multi-epitopic *in vivo* tumor associated antigen, other than a CA125, CA19.9 and CA15.3, present in a host's serum, which antigen does not elicit a host immune response, wherein the binding agent 5 specifically binds to a first epitope on the antigen and forms a binding agent/antigen pair wherein a host immune response is elicited against a second epitope on the antigen.

9        In certain embodiments the invention provides a therapeutic composition comprising a binding agent that binds an epitope of a soluble form of a cellular antigen which does not elicit a host immune response, in an amount sufficient to administer binding agent at a concentration between 0.1 $\mu$ g and 2 mg per kg of body weight of the host, wherein the binding agent specifically binds to the epitope and induces an immune response against the antigen.

13       In certain embodiments the invention provides a therapeutic composition for intravenous administration comprising a binding agent that binds an epitope of a soluble form of a cellular antigen which does not elicit a host immune response, wherein the binding agent specifically binds to the epitope and induces an immune 17 response against the antigen.

21       In certain embodiments the host immune response comprises a cellular and humoral immune response. In certain embodiments, the host immune response comprises a cellular response. In certain embodiments the host immune response 25 comprises a humoral response. In certain embodiments the antigen is a soluble antigen. In certain embodiments the binding agent is an antibody. In certain embodiments, the antibody is a murine monoclonal antibody. In certain embodiments the antibody does not induce HAMA in the host. In certain embodiments the antigen is associated with a human disease or pathological condition. In certain embodiments the disease or pathological condition is cancer. In certain embodiments the binding agent is photoactivated. In certain embodiments the humoral response comprises anti-idiotype antibodies. In certain embodiments, the amount of binding agent is at least 1  $\mu$ g and less than 2 mg, preferably between 1 $\mu$ g and 200  $\mu$ g per kg of body weight of the host.

29       Those skilled in the art will recognize that these embodiments may be used

1 alone, or in any combination.

5 In accordance with the present invention, the inventors believe the interaction between the antigen and the binding agent effectively presents a previously unexposed or suppressed epitope to the patient's immune system to generate: 1) a humoral response resulting in human anti-tumor antibodies that may or may not be inhibitable by the injected antibody, but are definitely inhibitable by an antibody that binds to an epitope different from the epitope reactive with the injected BA; and 2) a cell-mediated response resulting in the production of antigen-specific T-cells.

9 One skilled in the art will recognize that an aspect of any antibody-based immunotherapy is the interaction between the antigen and the antibody. Also, the success, effectiveness, and usefulness of that binding event typically involve a wide variety of sometimes interwoven factors. In general, these factors include but are not 13 limited to the binding capacity of the binding agent, immunogenicity of the binding agent, accessibility of the antigen, accessibility of the antigen's epitope, the degree of complementarity between the paratope of the binding agent and the epitope of the antigen, the effect of the binding event on the complex, the complex's capability of 17 inducing an immune response, and the extent to which the immune response is activated. It is intended that these factors contribute to the determination of an appropriate or desirable binding agent and/or pre-determined antigen, and to the nature and effectiveness of the resulting immune response.

21 The interplay of these various considerations, as taught by the present invention, may lead one to effective therapeutic remedies. In the case of B43.13 and the treatment 25 of ovarian cancer, a specific example used to prove the general point without thereby limiting the invention, B43.13 is a murine antibody, so its heterogeneity in a human system contributes to its immunogenicity. Further, CA 125, the target antigen, is a soluble, tumor associated antigen, and thereby accessible to a binding agent. The binding event between B43.13 and CA 125 is of such a nature that one or more new epitopes on the complex become available to components of the immune system, thus 29 inducing an immune response where previously there was none (or so little that no therapeutic benefit was derived). Further, the binding event created access to an epitope

1 on the complex that was suitable for inducing both humoral and cellular immune  
responses, thus inducing a comprehensive immune response that is itself a beneficial  
immune response. As pertains B43.13, all of these individual elements contributed to  
the recognition of the use of B43.13 to induce an immune response cascade that is  
5 effective in the treatment of ovarian cancer.

As noted above, the inventors believe that an important aspect of inducing or  
mediating a cellular and humoral response lies in part in increasing the immunogenicity  
of the binding agent-antigen complex while maintaining its antigenicity. As described  
9 in more detail below and in the Examples, increasing immunogenicity while  
maintaining antigenicity may be affected by one or more of the following:

1. Administering a dose of binding agent that is low in  
13 comparison to the dose for other therapeutic compositions;
2. Forming a binding agent-antigen complex *in vivo* or *ex vivo*;
3. Photoactivating the binding agent prior to administration
4. Administering the binding agent in a microsphere, liposome,  
17 nanosphere, or micelle;
5. Conjugating the binding agent to a photodynamic agent, such  
as hypocrellin B; and
6. Conjugating the binding agent to immune effectors.

21

In a preferred embodiment of the invention, a composition comprising a pre-determined antibody that specifically binds to a pre-determined tumor associated antigen is used to bind a soluble antigen produced by the tumor. Once the soluble  
25 antigen is bound, the immune system recognizes the antigen as "foreign," and mounts an immune response against the antigen or against the binding agent bound to the antigen. Antigens that can be made immunogenic are potentially useful to induce or activate an immune response, leading to therapeutic and possibly prophylactic benefits.

29

Any composition that includes a binding agent according to the invention may be used to initiate an *in vivo* immune response. The composition may include one or

1 more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more imaging reagents, one or more effectors; one or more photodynamic agents; and/or physiologically acceptable saline. Generally, adjuvants are substances mixed with an immunogen in order to elicit a more marked immune response. Control  
5 vaccinations without the adjuvant resulted in humoral immune responses. In a preferred embodiment of the invention, the composition comprising a binding agent does not include adjuvant.

In a preferred embodiment of the invention, a suitable composition includes a  
9 binding agent that binds to a soluble antigen to form a complex that is itself antigenic and immunogenic. In a most preferred embodiment of the invention, the complex is an antigen that induces a beneficial or desirable therapeutic effect.

The composition may also include pharmaceutically acceptable carriers.  
13 Pharmaceutically accepted carriers include but are not limited to saline, sterile water, phosphate buffered saline, and the like. Other buffering agents, dispersing agents, and inert non-toxic substances suitable for delivery to a patient may be included in the compositions of the present invention. The compositions may be solutions suitable for  
17 administration, and are typically sterile and free of undesirable particulate matter. The compositions may be sterilized by conventional sterilization techniques.

In accordance with the teachings of the present invention, the methods and compositions produce both a humoral and cellular response. Those skilled in the art  
21 will readily recognize that determining that a humoral and/or cellular response has been generated is easily shown by testing for the structures associated with each response. For example, evidence of the production of a humoral response includes but is not limited to the production of Ab2 and Ab3. Likewise, evidence of the production of a  
25 cellular response includes but is not limited to the production of T2 and/or T3 cells.

## BINDING AGENTS

The binding agents of the present invention bind an antigen of interest, and the  
29 resulting immunogenic pair or complex may be used to prime or initiate an immune response, typically to another epitope on the complex or a portion of the complex. The

1 previously unrecognizable epitope, upon being recognized by agents of the immune system, initiates the immune system cascade that results in a beneficial or therapeutic immune response to the whole antigen, and induces a comprehensive immune response.

5 A binding agent (BA), as used herein, refers to one member of a binding pair, including an immunologic pair, e.g., a binding moiety that is capable of binding to a single epitope expressed on the pre-determined antigen, such as a tumor antigen. The binding agent, when bound to the pre-determined antigen, forms an immunogenic complex. Exemplary binding agents include, but are not limited to: monoclonal 9 antibodies ("MAb"); chimeric monoclonal antibodies ("C-MAb"); humanized antibodies; genetically engineered monoclonal antibodies ("G-MAb"); fragments of monoclonal antibodies (including but not limited to "F( $Ab$ )<sub>2</sub>", "F( $Ab$ )" and "Dab"); single chains representing the reactive portion of monoclonal antibodies ("SC-MAb"); 13 antigen-binding peptides; tumor-binding peptides; a protein, including receptor proteins; peptide; polypeptide; glycoprotein; lipoprotein, or the like, e.g., growth factors; lymphokines and cytokines; enzymes, immune modulators; hormones, for example, somatostatin; any of the above joined to a molecule that mediates an effector 17 function; and mimics or fragments of any of the above. The binding agent may be labeled or unlabeled.

21 A binding agent according to the invention is preferably a monoclonal or polyclonal antibody. The antibody includes, but is not limited to native or naked antibodies; modified antibodies, such as activated or photoactivated antibodies. As used herein, native refers to a natural or normal antibody; naked refers to removing a non-native moiety, e.g., removing the label from a labeled antibody. In a most preferred embodiment of the invention, the binding agent is an Ab1 antibody that induces the 25 production of one or more molecules that comprise an immune response, including but not limited to one or more of the following: molecules associated with a cellular response (cytokines, chemokines, cytotoxic T lymphocytes (CTL), and natural killer cells (NK)), and/or molecules associated with a humoral response (Ab3, Ab1c 29 (sometimes referred to as Ab3')).

Methods for producing and obtaining an antibody are well known by those

1 skilled in the art. An exemplary method includes immunizing any animal capable of  
mounting a usable immune response to the antigen, such as a mouse, rat, goat sheep,  
rabbit or other suitable experimental animal. In the case of a monoclonal antibody,  
antibody producing cells of the immunized animal may be fused with "immortal" or  
5 "immortalized" human or animal cells to obtain a hybridoma which produces the  
antibody. If desired, the genes encoding one or more of the immunoglobulin chains  
may be cloned so that the antibody may be produced in different host cells, and if  
desired, the genes may be mutated so as to alter the sequence and hence the  
9 immunological characteristics of the antibody produced. Fragments of binding agents,  
may be obtained by conventional techniques, such as by proteolytic digestion of the  
binding agent using pepsin, papain, or the like; or by recombinant DNA techniques in  
which DNA encoding the desired fragment is cloned and expressed in a variety of hosts.  
13 Irradiating any of the foregoing entities, e.g., by ultraviolet light will enhance the  
immune response to a multi-epitopic antigen under similar conditions. In a preferred  
embodiment of the invention, effector functions that mediate CDC or ADCC are not  
required. Various binding agents, antibodies, antigens, and methods for preparing,  
17 isolating, and using the binding agents are described in U.S. Patent 4,471,057  
(Koprowski), U.S. Patent 5,075,218 (Jette, et al.), U.S. Patent 5,506,343 (Fufe), and U.S.  
Patent 5,683,674 (Taylor-Papadimitriou, et al), all incorporated herein by reference.  
Furthermore, many of these antibodies are commercially available from Centocor,  
21 Abbott Laboratories, Commissariat a L'Energie Atomique, Hoffman-LaRoche, Inc.,  
Sorin Biomedica, and FujiRebio.

One of the most promising approaches to tumor immunotherapy is to use  
antibody fragments or antibody fragments with effector domains to target and kill  
25 tumor cells. Single-chain Fv (scFv) has been genetically engineered as a recombinant  
fusion protein that is composed of a heavy chain (Vh) and a light-chain (Vl) variable  
domain connected by an artificial linker and an effector domain.

In an embodiment of the invention, a suitable composition for the treatment of  
29 an ovarian tumor associated antigen contains a binding agent that binds the CA 125  
antigen. Exemplary antibodies that bind to CA 125 include, but are not limited to

1 B43.13. The present invention also includes the use of any binding agent other than  
B43.13 that specifically binds to CA 125 and that results in a beneficial immune  
response, e.g., M11.

5 In another embodiment of the invention, a suitable composition for the  
treatment of gastrointestinal cancer contains a binding agent that binds the CA 19.9  
antigen. Exemplary antibodies that bind to CA 19.9 include, but are not limited to AR  
44.6, W25 (CIS Bio International), A3 (Shemyakin Inst. Biorg. Chem.), and NS116-NS-  
19.9 (Centocor), among others.

9 In yet another embodiment of the invention, a suitable composition for the  
treatment of breast cancer contains a binding agent that binds the CA 15.3 antigen.  
Exemplary antibodies that bind to CA 15.3 include, but are not limited to SM-3, DF-3,  
DF3-P, Ma 552, and BC4E549.

13 In yet another embodiment of the invention, a suitable composition for the  
treatment of prostate cancer contains a binding agent that binds the prostate specific  
antigen (PSA). An exemplary antibody that binds to PSA includes, but is not limited to  
AR47.47.

17

## SOLUBLE ANTIGEN

21 A pre-determined antigen may be any human or mammalian antigen of clinical  
significance. In accordance with the present invention, the pre-determined or target  
antigen must be capable of binding a binding agent. Capable of binding includes, but is  
not limited to one or more of the following: the antigen may be soluble, circulating,  
present, detectable, and/or include a binding site accessible to an administered binding  
agent.

25 In a preferred embodiment of the invention, the antigen is a tumor-associated  
antigen (TAA). In the case of TAA, the cancer may include, but is not limited to lung,  
colon, rectum, breast, ovary, prostate gland, head, neck, bone, immune system, or any  
other anatomical location. Illustrative tumors and tumor markers are listed in U.S.

29 Patent 5,075,218.

The methods of the present invention involve any cancer that produces a soluble

1 multi-epitopic TAA. As used herein soluble is used to describe any antigen that is  
detectable in a body fluid, i.e., blood, serum, ascites, saliva, or the like. In accordance  
with the present invention, the preferred tumors are those that: shed soluble tumor  
antigens, e.g., tumor antigens shed into the bloodstream, as opposed to a surface antigen  
5 or an intracellular antigen; exhibit a multi-epitopic tumor associated antigen, and can be  
found at a concentration in the patient's body fluid more than is normally present in  
healthy controls and such a high level signifies presence of the disease, yet has not  
initiated a significant immune response. In a preferred embodiment, the pre-determined  
9 antigen is an antigen that does not elicit a host immune response, e.g., is not effective in  
reducing tumor burden and/or does not induce a therapeutic benefit (even if a small  
immune response is generated). As is well known by one skilled in the art, one method  
of determining whether the concentration of the TAA is greater than in healthy  
13 individuals is by comparing the patient's concentration to that of a healthy control. If  
the concentration of the TAA is higher than the healthy control, then the patient's  
concentration is predictive of presence or recurrence of the disease.

17 The invention also involves the production of a modified antigen, typically by  
producing the modified antigen *in vivo*. As used herein, modified antigen refers to a  
first antigen, typically invisible to the immune system, that binds to a binding agent,  
and the binding agent-antigen is itself an antigen (the "second" antigen) that is  
immunoreactive with one or more molecules of the immune system.

21 As used herein, "disease" refers to the management, diagnosis, and/or palliation  
of any mammalian (including human) disease, disorder, malady, or condition. "Disease"  
includes but is not limited to cancer and its metastases, such as skin cancer; growths or  
tumors, and their metastases; tumors and tumor cells, such as sarcomas and carcinomas,  
25 including solid tumors, blood-borne tumors, and tumors found in nasal passages, the  
bladder, the esophagus, or lung, including the bronchi; viruses, including retroviruses  
and HIV; infectious diseases, such as hepatitis, including chronic hepatitis such as  
hepatitis B; bacterial diseases; fungal diseases; and dermatological conditions or  
disorders, such as lesions of the vulva, keloid, vitiligo, psoriasis, benign tumors,  
29 endometriosis, Barrett's esophagus, *Tinea capitis*, and lichen amyloidosis. Exemplary

1 soluble multi-epitopic antigens are described above, and include but are not limited to  
CA 125, CA 19.9, CA 15.3, polymorphic epithelial mucin (PEM), CEA, and prostate  
specific antigen.

5 A high level of antigen, as used herein, is a variable term dependent in part on  
the type of the antigen, and/or the type of disease or condition, and/or the stage of the  
disease or condition. For example, one skilled in the art will recognize that a high level  
may mean that a majority of cancer-positive patients, e.g., above 50% or above about  
80%, have a certain amount of circulating antigen. For example, the present  
9 understanding of the course of ovarian cancer suggests that 80% or higher of the patients  
having greater than 35 U/ml of antigen in their bloodstream have a statistically  
significant higher risk of developing ovarian cancer. A high level also may be defined in  
terms of the amount sufficient to completely or substantially completely bind all of a  
13 pre-determined dose of binding agent. A high level may also be defined as a threshold  
quantity of circulating antigen that those skilled in the art recognize as a high level. A  
high level may also include that amount that is predictive of disease. A high level may  
also include an amount or concentration of antigen higher than what is normal for that  
17 patient or for that disease or condition.

21 A method of an embodiment of the invention includes determining the amount  
of pre-determined antigen in the patient, e.g., circulating in the patient, and if the  
amount of antigen is a high level, then administering a composition comprising a  
binding agent according to the invention. For example, a method of the invention  
includes determining the amount of circulating CA 125, and if the amount is greater  
than about 35 U/ml, then administering a composition comprising a binding agent  
according to the invention, e.g., comprising B43.13. The administered composition  
25 may include a low dose of binding agent.

29 As noted in the background section, the potential effect of injecting a binding  
agent such as an antibody can be extremely complex and may typically involves distinct  
mechanisms of action. As used in herein, Ab3 and Ab1c represent two such distinct  
mechanisms that individually and/or collectively produce a beneficial effect. In the Ab3  
pathway, an Ab1 antibody that is capable of binding to a pre-determined antigen may

1 induce the production of an anti-idiotype antibody (Ab2 $\beta$ ) that mimics an epitope of the  
antigen. The anti-idiotype antibody in turn may induce the production of anti-anti-  
idiotype antibodies (Ab3) that are capable of binding the same epitope on the antigen as  
the Ab1 antibody. Evidence of this pathway includes a competitive assay between Ab1  
5 and Ab3, since the Ab1 antibody and the Ab3 antibody compete for the same epitope of  
the antigen.

9 In the Ab1c pathway, the Ab1 antibody binds to the antigen to form a complex.  
This complex is itself an antigen, and is sometimes described herein as a "modified  
antigen" or second antigen. The complex may induce the production of anti-antigen  
antibody (Ab1c) that are capable of binding a different epitope on the antigen as that  
bound by the Ab1 antibody. Evidence of this pathway also includes a competitive  
assay, but comparing the inhibitory effect on Ab1c by antibodies that bind to different  
13 epitopes on the antigen or lack of inhibition with Ab1.

17 In addition to producing Ab3 and/or Ab1c, typically associated with a humoral  
immune response, the compositions of the present invention may also produce a  
therapeutic benefit by inducing a cellular immune response (cell mediated immunity), as  
in the Background section. Both the cellular and the humoral response involve indirect  
mechanisms for altering the immunogenicity of the host.

21 Compositions of the present invention may also initiate direct mechanisms for  
killing undesirable cells such as cancer cells. For example, in antibody-dependent cell-  
mediated cytotoxicity (ADCC), an Ab1 antibody, bound through its Fab region to a  
pre-determined antigen, may bind to the Fc receptor of a lymphocyte through the Fc  
region of the Ab1 antibody. Such participation between an antibody and immune  
system cells produces an effector function that may lyse tumor cells, infectious agents,  
25 and allogeneic cells. Other indirect mechanisms involve complement-mediated  
cytotoxicity (CDC), apoptosis, (neutralization of immunosuppressive tumor-associated  
antigens), induction of cytokines and/or chemokines, neutralization of  
immunosuppressive molecules, and neutralization of anti-adhesion molecules, among  
29 others.

As used herein, a comprehensive approach to providing a therapeutic benefit

1 involves one or more, or all, of the following: cellular immunity and the molecules involved in its production; humoral immunity and the molecules involved in its production; ADCC immunity and the molecules involved in its production; CDC immunity and the molecules involved in its production; natural killer cells; and

5 cytokines and chemokines, and the molecules and cells involved in their production.

One skilled in the art will recognize that a beneficial immune response (and thereby overcoming immunotolerance) may be determined by a number of ways. Activation of the multiple arms of the immune systems may be determined, for example, by

9 measuring the pre- and post-treatment antigen specific immune response. Specific demonstrations of the induction of a beneficial immune response would include one or more of the following:

13 1) a humoral response to the administered antibody (Ab1), including evidence of HAMA and/or Ab2;

17 2) a humoral response to the antigen, including evidence of the appearance of antigen-specific antibodies to the same and/or different epitopes on the antigen as the epitope for the binding agent (e.g., Ab3 and/or Ab1c);

21 3) antibody-dependent cytotoxicity, including evidence that post-injection sera with an antigen-specific antibody titer mediates tumor killing when the sera is incubated peripheral blood mononuclear cells and tumor cell targets relative to pre-injection baseline serum;

25 4) complement-dependent cytotoxicity, including evidence that post injection sera combined with complement-containing plasma kills tumor cell targets relative to pre-injection baseline serum;

29 5) natural killer cell activity, including enhanced tumor cell killing by peripheral blood mononuclear cells (containing NK cells) in post-injection blood samples taken prior to the appearance of a measurable antibody response to the TAA relative to pre-treatment peripheral blood mononuclear cells;

6) antigen-enhanced cytotoxicity, including enhanced tumor cell target killing by peripheral blood mononuclear cells (in the presence of TAA-positive tumor cells) relative to pre-administration levels; and

1           7) cellular immunity, including evidence of T cell proliferation or tumor cell  
lysis post-injection relative to pre-injection.

5           Further, evidence of a beneficial immune response may include demonstrating  
that the binding agent-antigen complex results in a more vigorous T cell proliferative  
response than the response to either the binding agent or the antigen alone (in post-  
treatment PBMC versus pre-treatment). One skilled in the art will also recognize that  
this battery of evidence demonstrates that the compositions and methods of the present  
invention induce multiple different immune system pathways, and that these various  
9           pathways have varying relative importance to a particular patient, depending on the  
individual's specific immune constitution.

## IMMUNOGENICITY ENHANCERS

### 13           1. LOW DOSE

17           In accordance with the methods of the present invention, a composition  
comprising the binding agent may be administered in an amount sufficient to recognize  
and bind the pre-determined antigen, such as a tumor associated antigen (TAA),  
preferably a soluble multi-epitopic antigen. In a preferred embodiment of the  
invention, the dosage is sufficient to generate or elicit an immune response against the  
antigen. See Example 16. An immunologically or therapeutically effective or  
acceptable amount of binding agent is an amount sufficient to bind a pre-determined  
21           antigen *in vivo or ex vivo*, and is capable of eliciting an immune response to the antigen.  
The response inhibits or kills tumor cells that carry and present a newly accessible  
epitope, thereby ameliorating or eliminating the disease or condition that produces the  
antigen. The immune response may take the form of a humoral response, a cell-  
mediated response, or both. In a preferred embodiment of the invention, the dosage of  
25           the monoclonal antibody is less than the dosage required to elicit ADCC or CDC.

29           The concentration or dosage of the protein in the composition can vary widely,  
e.g., from less than about .01% to about 15 to 20% by weight. As noted above, the  
composition is administered in an amount sufficient to stimulate an immune response  
against the antigen. Amounts effective for this use will depend in part on the severity of

1 the disease and the status of the patient's immune system. Generally, the composition  
will include about 0.1  $\mu$ g to about 2 mg or more of protein agent per kilogram of body  
weight, more commonly dosages of about 1  $\mu$ g to about 200  $\mu$ g per kilogram of body  
weight, recognized by those skilled in the art as comprising a low dose. Further, those  
5 skilled in the art will recognize and be able to evaluate the various considerations that  
may be used to determine a proper dose. The concentration will usually be at least  
0.5%; any amount may be selected primarily based on fluid volume, viscosity,  
antigenicity, etc., in accordance with the particular mode of administration.

9 A method and composition of an embodiment of the invention includes a  
composition comprising a low dose of a binding agent, wherein low dose refers to an  
amount less than about 2 mg/kg of body weight, even more preferably, between about  
0.1  $\mu$ g to about 2 mg per kilogram of body weight, and wherein the administration of  
13 the composition comprising a low dose of binding agent induces a beneficial immune  
response.

## 2. PHOTOACTIVATION

17 In accordance with the present invention, an antibody may be photoactivated.  
Processes for photoactivating a binding agent are extremely well known in the art, and  
include exposing the antibody to radiation, wherein the resulting altered antibody is  
capable of generating an immune response when administered to an animal typically  
21 capable of generating an immune response to the native form of the antibody.

In a preferred embodiment of the invention, the antibody is exposed to  
ultraviolet light. Typically, the antibody may be exposed to ultraviolet light at a  
wavelength from about 200 nm to about 400 nm, at from about .1 to about 1000  
25 Joules/cm<sup>2</sup>, for from about 1 to about 180 minutes (more preferably, about 10 to about  
30 minutes).

## 3. DELIVERY SYSTEM

29 Since some binding agents such as proteins are by themselves poor immunogens,  
their immunogenicity may be augmented by administration in immunological adjuvants

1 and antigen delivery systems. The immunogenicity of a specific composition may also  
be increased or optimized by choice of delivery route. For example, the  
immunogenicity of compositions produced in accordance with the present invention  
that include a monoclonal antibody may be increased by choosing a mode of delivery  
5 that increases the direct contact between the binding agent and the antigen. The  
preferred route is intravenous. Those skilled in the art are conversant with the various  
choices available, and why one route might be chosen over another route for a  
particular binding agent.

9 One skilled in the art will also recognize that liposomes, nanospheres, micelles,  
or microspheres may be used to administer a composition, and that such administration  
may increase immunogenicity.

13 4. PHOTORESENSITIZER

Compositions of the present invention may include one or more  
photosensitizers. Exemplary photosensitizers include, but are not limited to  
fluorescein, hematoporphyrin derivatives (e.g., Photofrin®), porphyrin derivatives, and  
17 perylenequinoid pigments. In a preferred embodiment of the invention, the  
photosensitizer comprises the use of perylenequinone (PQP) derivatives as  
photodynamic agents, and the use of PQP derivatives in immunophotodynamic therapy  
(IPT).

21 The invention also comprises a method of treating a disease by administering a  
therapeutically sufficient amount of at least one PQP derivative bound to a binding  
agent, and activating the conjugate, typically by photoactivating the PQP derivative.  
Typically, the PQP derivative may be activated by exposing the derivative to a pre-  
25 determined wavelength of light. The invention also includes a method of treating  
cancer which is enhanced in the presence of light wavelengths between about 400 nm  
and about 850 nm. Suitable PQPs include, but are not limited to those disclosed in U.S.  
Serial No. 08/782,048, incorporated herein by reference. In a preferred embodiment of  
29 the invention, the PQP is hypocrellin B, molecules derived from HB, and compositions  
that include HB or one or more of its derivatives.

1        The desired characteristics for a PDT sensitizer comprise at least one or more of  
the following characteristics: good absorption of light in a wavelength that penetrates  
tissue to the desired depth (absorption in the 600 nm to 850 nm range penetrate the skin  
many mm), compound sensitive to pH - inactive, lower activity or activity destroyed at  
5        the pH characteristic of normal tissues, but active or higher activity at the pH of the  
cells or organisms to be treated; compound cleared from the body quickly and if a  
compound is intended to treat solid tumors it should have the ability to function either  
in the presence and/or absence of oxygen to address the problem of tumor cell hypoxia.  
9        The photosensitizer should have low dark cytotoxicity, and excellent photopotentiation  
of cellular damage. The PDT toxic effect may be mediated via necrotic, apoptotic cell  
death, or by stasis of the tumor vasculature or vascular bed.

13        5. EFFECTORS

17        The present invention includes a composition comprising a binding agent bound  
to or used in conjunction with one or more effectors. As used herein, effector refers to  
a substance that affects the activity of the binding agent without binding to the substrate  
(or antigen) binding site.

21        A conceptually straightforward method to functionalize recombinant antibodies  
consists of sequentially fusing the antibody gene with the gene of a second protein, and  
expressing the resulting fusion protein as a single protein. Exemplary second proteins  
include but are not limited to:

- 25        a. A signal amplification moiety, such as a biotin mimetic sequence, which can  
be introduced at the C-terminus of a binding agent as a detection tag because of strong  
affinity of streptavidin-biotin;
- b. Liposomes: fusion of certain amino acid sequences (with negative charges  
under physiologic condition) with a binding agent, such as single chain Fv-B43.13.  
Therefore, the fusion protein can easily be trapped by liposomes;
- 29        c. Cytokine sequences (e.g. IL-2): IL2 is a lymphokine synthesized and secreted  
primarily by T helper lymphocytes which have been activated by stimulation of the T  
cell receptor complex with antigen/MHC complexes on the surfaces of antigen-

1 presenting cells. The response of T helper cells to activation is induction of the  
expression of IL2 and of IL2 receptors. IL2 possesses a variety of other activities which  
affect B cell growth and differentiation, formation of LAK cells, and augmentation of  
NK cells and enhancement of their cytolytic activity. Because of the central role of the  
5 IL2/IL2 receptor system in mediation of the immune response, it is obvious that  
manipulation of this system has important therapeutic implications. IL2 has already  
shown promise as an anti-cancer drug by its ability to stimulate the proliferation and  
activities of tumor attacking LAK and TIL cells.

9 d. Toxin: immunotoxins made by attaching a toxin (e.g. *Pseudomonas* exotoxin  
and bacteria RNase) to the antibody or antibody fragments to produce cytotoxic  
molecules that selectively kill target tumor cell.

13 e. Enzyme: an antibody-directed enzyme pro-drug therapy system is a  
particularly attractive artificial effector method. In this approach, an antibody is used to  
target an enzyme to the tumor, and to retain it while the antibody-enzyme conjugate  
clears from normal tissues. A non-toxic pro-drug is then administrated, and this is  
activated by the enzyme to produce a cytotoxic drug at the tumor site.

17 f. Radionuclide chelator: any peptide that binds to a radionuclide chelator, e.g.,  
metallothionein (MT). MT is a ubiquitous, low-molecular weight, metal-binding  
protein that participates in metal metabolism and detoxification. Mammalian forms of  
MT bind seven ions in tetrahedral metal-thiolate clusters, including technetium and  
21 other metals useful for targeted radiodiagnosis or therapy.

25 g. A phagocytosis enhancer, e.g., tuftsin. Tuftsin is natural tetrapeptide (Thr-  
Lys-Pro-Arg) that was found to manifest several biological activities, including  
activation of macrophages/monocytes and stimulation of phagocytosis. It has a wide  
spectrum of immunoadjuvant activities which it exerts on the phagocytic cells, the  
polymorphonuclear leukocyte, the monocyte and the macrophage. In animal and  
clinical studies, tuftsin has displayed anti-tumor and anti-infection activity with no  
detectable toxicity.

29 The fusion protein scFv-tuftsin was defined as a recombinant fusion protein that  
is composed scFv antibody binding domain connected with tuftsin by an artificial

1 linker. This bi-functional protein was designed to achieve higher specific anti-idiotypic  
immunogenicity.

## METHOD

5 In an embodiment of the invention, MAb B43.13, directed against a first epitope  
on the multi-epitopic antigen CA 125, induces an immune response against CA 125  
through one or more second epitopes on the CA 125 antigen. In a preferred  
embodiment of the invention, any of the second epitopes are cryptic or previously  
9 inaccessible epitopes that are exposed or available for interacting with a component of  
the immune system reaction after MAb B43.13 binds to the antigen. Cryptic or  
previously inaccessible refers to an epitope or binding site on the pre-determined  
antigen that does not activate or stimulate the immune system when the antigen is  
13 unbound by a binding agent according to the invention.

As used herein, "administering" refers to any action that results in exposing or  
contacting a composition containing a binding agent with a pre-determined cell, cells, or  
tissue, typically mammalian. As used herein, administering may be conducted *in vivo*,  
17 *in vitro*, or *ex vivo*. For example, a composition may be administered by injection or  
through an endoscope. Administering also includes the direct application to cells of a  
composition according to the present invention. For example, during the course of  
surgery, tumor cells may be exposed. In accordance with an embodiment of the  
21 invention, these exposed cells (or tumors) may be exposed directly to a composition of  
the present invention, e.g., by washing or irrigating the surgical site and/or the cells.

For diseases that can be characterized in part by having a tumor-associated  
antigen that is multi-epitopic, the present invention involves contacting a soluble  
25 antigen with a binding reagent (BA) that specifically binds to a single epitope on the  
multi-epitopic tumor-associated antigen.

In accordance with a method of the invention, the binding agent must be capable  
of binding a pre-determined binding site or receptor, and may be administered to the  
29 patient by any immunologically suitable route. For example, the binding agent may be  
introduced into the patient by an intravenous, subcutaneous, intraperitoneal,

1 intrathecal, intravesical, intradermal, intramuscular, or intralymphatic routes. The  
composition may be in solution, tablet, aerosol, or multi-phase formulation forms.  
Liposomes, long-circulating liposomes, immunoliposomes, biodegradable microspheres,  
micelles, or the like may also be used as a carrier, vehicle, or delivery system.  
5 Furthermore, using *ex vivo* procedures well known in the art, blood or serum from the  
patient may be removed from the patient; optionally, it may be desirable to purify the  
antigen in the patient's blood; the blood or serum may then be mixed with a  
composition that includes a binding agent according to the invention; and the treated  
9 blood or serum is returned to the patient. The clinician may compare the anti-idiotypic  
and anti-isotypic responses associated with these different routes in determining the  
most effective route of administration. The invention should not be limited to any  
particular method of introducing the binding agent into the patient.

13 Administration may be once, more than once, and over a prolonged period. As  
the compositions of this invention may be used for patient's in a serious disease state,  
i.e., life-threatening or potentially life-threatening, excesses of the binding agent may be  
administered if desirable. Actual methods and protocols for administering  
17 pharmaceutical compositions, including dilution techniques for injections of the present  
compositions, are well known or will be apparent to one skilled in the art. Some of  
these methods and protocols are described in *Remington's Pharmaceutical Science*, Mack  
Publishing Co. (1982).

21 A binding agent may be administered in combination with other binding agents,  
or may be administered in combination with other treatment protocols or agents, e.g.,  
chemotherapeutic agents.

25 The effectiveness of the proteins of the present invention may be monitored *in*  
*vitro* or *in vivo*. Humoral responses may be monitored *in vitro* by conventional  
immunoassays, where the anti-tumor activity of the response may be determined by  
complement-mediated cytotoxicity and/or antibody-dependent cellular cytotoxicity  
(ADCC) assays. The assay methodologies are well known, and are described in  
29 *Handbook of Experimental Immunology*, Vol. 2, Blackwell Scientific Publications,  
Oxford (1986). Other assays may be directed to determining the level of the antigen in

1 the patient or tissue. Cell-mediated immunity may be monitored *in vivo* by the  
development of delayed-type hypersensitivity reactions, or other *in vivo* or *in vitro*  
means known to those skilled in the art, including but not limited to the skin test  
reaction protocol, lymphocyte stimulation assays, measuring the toxicity of a subject's  
5 lymphocytes to tumor cells by using a standard cytotoxicity assay, by a limiting  
dilution assay, or by measuring plasma levels of cytokines using standard ELISA assays.

9 Determining the effectiveness of a specific binding agent - antigen pair may also  
be accomplished by monitoring cell killing. Those skilled in the art will recognize that  
there are a variety of mechanisms that are proof of cell killing. As shown in the  
Examples, cell killing may be demonstrated by showing that Ab3 mediates ADCC, that  
Ab1 and HAMA mediates CDC, that natural killer (NK) cells are produced, and/or  
that cytotoxic T lymphocytes (CTLs) are produced.

13

## EXAMPLES

### Example 1. Antibody mediated immunotherapy influence of circulating antigen in inducing antigen specific anti-tumor immune responses.

17

This example demonstrates the use of antigen-specific murine monoclonal antibodies to induce an immune response against an immune-suppressive tumor-associated antigen. Injecting an antibody against a specific epitope in a multi-epitopic antigen can lead to immune responses against various other epitopes on this antigen.

21

In an attempt to understand the mechanism of action of MAb-B43.13, various immunological parameters were studied in patients injected with this antibody. These studies clearly demonstrated activation of both the humoral and cellular anti-cancer immune responses.

25

The generation of human CA125-binding antibodies was measured before MAb-B43.13 injection and correlated to pre-injection CA125 levels as well as to survival data. Table 1 shows that generation of anti-CA125 antibodies correlates with CA125 pre-injection levels. Circulating CA125 affects the development of anti-CA125 antibodies only when patients received the MAb-B43.13 injection. If anti-CA125 antibodies before injection of MAb-B43.13 are compared between patients with low or high CA125

1 values (below or above 100 U/mL), no difference was found between the two groups  
(Table 1). A minimum concentration of 100 U/mL of CA125 was chosen as  
representing a significant amount of CA 125.

5 Tumor killing either through an anti-CA125 antibody-mediated ADCC  
mechanism or through CA125-specific CLTs, lead to increased survival in patients  
injected with MAb-B43.13. Although high levels of serum CA125 have been suggested  
to be a poor prognostic indicator, they seem to have a beneficial effect in combination  
with the injection of anti-CA125 antibody in such patients. For example, when the  
9 CA125 levels were more than 100 units/mL, immune response against CA 125  
increased by more than 20% which in turn increased the median survival in those  
patients from 39.1 months to 54.5 months (Table 1). Thus the injection of a binding  
agent to a patient containing elevated levels of multiepitopic soluble antigen leads to  
13 antigen specific humoral and cellular response which in turn leads to tumor killing  
followed by improved survival.

17 TABLE 1: Correlation between Serum CA125 Levels, Human Anti-CA125 (Ab<sub>1</sub>')

Response and Survival in Patients Injected with MAb-B43.13

Preinjection Serum CA125 Level	%-age of Patients with Human Anti-CA125 Response	Mean Survival in Month
< 100 U/mL	10.3%	39.1
> 100 U/mL	32.6%	54.5

25

29

1      **TABLE 2: Correlation between Serum CA125 Levels and Antibody Levels in Patients**  
2      **Injected with MAb-B43.13.**

5	Pre-injection Serum CA125 Level	Anti-CA125 Antibody Titre (No. of Positive/Total Patients)
	< 100 U/mL	3/29
9	> 100 U/mL	15/46

The correlation between CA125 antibodies and survival, with a CA 125 cut-off of  $10^5$  U/ml is shown in Table 4.

Table 4

anti-CA125 Antibodies							
		n	[ng/ml]	P	[ <i>fold increase</i> ]	P	mean $\pm$ SD
5	Anti-CA125 Non-Responders	27	61.8 $\pm$ 25.1	0.0031	1.3 $\pm$ 0.7	<0.0001	34.8 $\pm$ 18.2
	Anti-CA125 Responders	20	346.4 $\pm$ 376.3		7.4 $\pm$ 5.1		67.6 $\pm$ 27.0
	CA125 < 105 U/ml	19	94.0 $\pm$ 61.0	0.0213	2.4 $\pm$ 1.3	0.0089	46.1 $\pm$ 26.8
	CA125 > 105 U/ml	28	239.8 $\pm$ 308.8		5.3 $\pm$ 5.2		50.5 $\pm$ 28.3
9	Anti-CA125 Non-Responders						
	CA125 < 105 U/ml	12	53.8 $\pm$ 12.0	0.1146	1.6 $\pm$ 0.7	0.8448	38.5 $\pm$ 23.5
	CA125 > 105 U/ml	15	68.2 $\pm$ 31.0		1.5 $\pm$ 0.7		31.8 $\pm$ 12.6
	Anti-CA125 Responders						30.0
13	Anti-CA125 Non-Responders						
	CA125 < 105 U/ml	7	162.9 $\pm$ 46.1	0.0152	3.9 $\pm$ 0.4	0.0009	51.9 $\pm$ 24.0
	CA125 > 105 U/ml	13	445.2 $\pm$ 357.8		9.6 $\pm$ 4.7		76.0 $\pm$ 25.4
	CA125 < 105 U/ml						82.0
17	Anti-CA125 Non-Responders	12	53.8 $\pm$ 12.0	0.0006	1.6 $\pm$ 0.7	<0.0001	38.5 $\pm$ 23.5
	Anti-CA125 Responders	7	162.9 $\pm$ 46.1		3.9 $\pm$ 0.4		51.9 $\pm$ 24.0
	CA125 > 105 U/ml						45.0
	Anti-CA125 Non-Responders	15	68.2 $\pm$ 31.0	0.0025	1.5 $\pm$ 0.7	<0.0001	31.8 $\pm$ 12.6
	Anti-CA125 Responders	13	445.2 $\pm$ 357.8		9.6 $\pm$ 4.7		76.0 $\pm$ 25.4
							82.0

1        In an attempt to understand the mechanism behind anti-CA125 antibody formation  
by MAb-B43.13 injection in cancer patients, we characterized the human anti-CA125  
antibodies present in their sera. For example, if the anti-CA125 antibodies were generated  
in the manner suggested by the idiotypic network, MAb-B43.13 would generate anti-MAb-  
5        B43.13 antibodies, some of which would exactly mimic the CA125 antigen (= Ab2 $\beta$ ).  
These in turn can generate anti-CA125 antibodies (= Ab3). The Ab3 generated through this  
pathway would bind to the same epitope on CA125 as the Ab1 (=B43.13) and therefore  
compete with the binding of MAb-B43.13 to the antigen.

9        On the other hand, antibodies generated through the antigen itself will bind to  
various epitopes available on the antigen. If the anti-CA125 antibodies were generated in a  
manner suggested by the present invention, the pathway would follow Ab1 + soluble  
13        antigen → Ab1c. Following this scheme, MAb-B43.13 (Ab1) would bind the CA125 serum  
antigen, which would in turn generate an anti-CA125 antibody (Ab1c). Furthermore, the  
Ab1c antibodies generated under this pathway would bind and be inhibited by other anti-  
CA 125 antibodies, such as B27.1 or M11, because, as noted above, CA125 is multi-epitopic  
and B43.13, M11, and B27.1 epitopes are distinct. Also, Ab1c will not bind to anti-MAb-  
17        B43.13 antibodies.

21        Analysis of the serum samples with positive anti-CA125 titer demonstrated that  
their binding to CA125 could be inhibited not only by MAb-B43.13 single chain antibody  
but also by F(ab') fragments of other anti-CA125 antibodies, B27.1 and M11, that recognize  
epitopes on CA125 which are different from B43.13 (Tables 3 and 4). Sera from only two  
patients were considered to contain anti-CA125 antibodies that were exclusively generated  
via idiotype induction of MAb-B43.13 (=Ab3) i.e. anti-CA125 antibodies that could only  
and completely be inhibited with MAb-B43.13 and bound to polyclonal rabbit Ab2.

25        Thus, if the patients serum contained anti-CA125 antibodies that were inhibitable  
by MAb-B43.13 only, it was classified as containing Ab3; those inhibitable by MAb-B27.1  
were classified as Ab1c. In other words, injecting a binding agent such as an antibody  
against a single epitope on a multi-epitopic antigen leads to generation of a humoral and

1 cellular response against a different epitope on the antigen.

The presence of a multi-epitopic anti-CA125 response in sera of MAb-B43.13 treated patients with high CA125 levels make us believe that, besides anti-idiotype induction, other mechanisms exist to induce an immune response against tumor-associated antigens. In this scenario, the injected antibody forms a complex with the circulating antigen *in vivo*. This process can cause several effects. The complexation of the antigen by antibodies can facilitate the uptake of CA125 by professional antigen-presenting cells (APC) and thus render the antigen more immunogenic. The complexing antibody – in our case from a murine source – could also function as an adjuvant, adding a foreign component to the self-antigen CA125 that might facilitate recognition by the immune system. Epitopes of the antigen are blocked by the complexing antibody and are either protected from processing or processed at different sequences thus creating new peptides for MHC-binding. It is also possible that a conformational change in the antigen takes place upon antibody binding thereby exposing new epitopes to the immune system, including sub-dominant or immune-dormant epitopes.

It is interesting to note that the complex formation between CA125 and MAb-B43.13 has also been observed during pharmacokinetic studies, as determined by drop in circulating CA125 levels upon injection of MAb-B43.13. When patients received more than one injection and patients developed high amounts of human anti-mouse antibodies (HAMA), the antibody showed rapid clearance to liver and spleen, as demonstrated in immunoscintigraphic studies. Antigen-antibody complexes, accumulated in lymphoid centers like the spleen, are known to be very efficiently presented to T cells by antigen-presenting cells, such as B cells, macrophages, or dendritic cells.

Augmentation of antigen processing and presentation by immune complexing has been demonstrated in several systems. Targeting tetanus toxoid to Fc<sub>Y</sub>R by complexing with anti-tetanus toxoid IgG results in a 10-1000-fold increase in processing and presentation of this antigen as measured by T<sub>H</sub> cell activation. A similar increase in immunogenicity was observed with hepatitis B antigen complexed with its corresponding

1 antibody. Also the natural presence of antibodies against  $\alpha$ -galactosyl epitopes has been  
used to augment tumor vaccine immunogenicity in  $\alpha$ -galactosyl -modified tumor-associated  
antigens.

5 It was observed that MAb-B43.13 has a protective effect on its CA125 epitope  
during antigen processing by the immune system. The MAb-B43.13 epitope was recognized  
by almost all anti-CA125 antibody samples from patients (inhibition in 78% of the samples,  
Table 4).

9 The reverse seems to be true as well, i.e. CA125 has conserving properties on the  
idiotope of MAb-B43.13 during the antigen processing event. The increased formation of  
Ab2 in mice immunized with the CA125-MAb-B43.13 complex compared to mice  
immunized with MAb-B43.13-KLH (Figure 3) and the increased Ab2 production in MAb-  
B43.13 injected patients with CA125 titers above 100 U/mL confirm this observation. See  
13 Table 4 and Figure 6 for a summary and Table 5 for the details of these results. Sera from  
these patients were analyzed for the presence of human anti-CA125 antibodies by their  
ability to bind to CA125 [R. Madiyalakan et al, *Hybridoma*, 14:199-203 1995) and Schultes  
et al., *Cancer Immunology and Immunotherapy* 46:201-212 (1998)]. Antibody purified from  
17 pooled patients' sera were found to inhibit B43.13 in similar assays, but not B27.1. The  
explanation for this anomaly is yet to be determined. However, it has been confirmed  
using M11 antibodies that B43.13 binds to a distinct epitope, and that upon binding with  
B43.13, CA 125 is in fact recognized by the immune system.

21

25

1

Table 3

5

9

Inhibition			
No. of Positives/Total			
(%)			
CA125 10000 U/ml	B43.13 scFv 1 $\mu$ g/ml	B27.1 F(ab') 1 $\mu$ g/ml	M11 F(ab') 1 $\mu$ g/mL
26/28	22/28	11/28	8/19
(92.8)	(78.6)	(39.3)	(42.1)

TABLE 4: Characterization of Anti-CA125 Antibodies in Patients Injected with MAbs-B43.13

1

Patient	Inj #	days post- inj.	Anti- CA125 Ab levels (ng/mL)	Binding to anti-MAb B43-13 (AB2)†	Inhibition (%) <sup>1</sup>				Classification
					CA125 10000 U/mL	B43.13 ScFv <sup>2</sup> 10 µg/mL	B27.1 F(ab') <sup>2</sup> 1 µg/mL	M11 F(ab') <sup>2</sup> 1 µg/mL	
1	3	0	14.8	+	62.3	42.6	5.8	2.3	Ab3
2	1	185	9.5	-	21.6	-46.9 <sup>3</sup>	-86.9 <sup>3</sup>	24.3	Ab1c
3	2	239	45.4	+	89.7	95.3	12	ND	Ab3
	3	86	25.4	+	80.2	84.4	-05 <sup>3</sup>	2.1	Ab3
	3	207	48.7	+	91.4	94.0	-9.1 <sup>3</sup>	ND	Ab3
4	144	79.7	+	77.1	93.0	3.5	4.5	Ab3	
	4	270	30.9	+	79.2	83.0	-55.8 <sup>3</sup>	ND	Ab3
	4	309	16.7	+	77.0	83.0	-55.8 <sup>3</sup>	ND	Ab3
5	45	16.0	+	51.6	50.9	34.8	ND	Ab3/Ab1c	
	5	134	64.1	+	89.1	83.3	-37.3 <sup>3</sup>	-2.3	Ab3
4	2	15	23.6	-	62.3	-84.8 <sup>3</sup>	-101.9 <sup>3</sup>	18.5	Ab1c
	2	41	21.6	-	56.9	20.2	-7.0 <sup>3</sup>	ND	Ab1c
	2	76	23.1	-	63.6	29.4	4.5	ND	Ab1c
3	28	11.1	-	24.2	4.7	11.1	35.6	Ab1c	

Patient	Inj #	days post-inj.	Anti-CA125 Ab levels (ng/mL)	Binding to anti-MAb B43-13 (AB2)†	Inhibition (%) <sup>1</sup>				Classification
					CA125 10000 U/mL	B43.13 ScFv <sup>2</sup> 10 $\mu$ g/mL	B27.1 F(ab') <sup>2</sup> 1 $\mu$ g/mL	M11 F(ab') <sup>2</sup> 1 $\mu$ g/mL	
1	5	1	16	15.5	+	74.8	78.3	39.9	-12.5
	6	3	0	10.3	+	54.0	60.2	22.7	1.5
	7	3	0	14.9	-	29.7	-70.2 <sup>3</sup>	-358.9 <sup>3</sup>	ND
	8	3	7	59.1	-	77.1	87.1	34.9	12.5
	9	3	17	46.9	-	78.4	86.5	40.7	9.6
5	9	3	112	9.2	-	-66.4 <sup>3</sup>	16.0	20.2	45.6
	10	3	166	8.5	-	-18.4 <sup>3</sup>	42.5	56.5	33.8
	11	3	0	41.5	-	30.8	39.2	20.0	57.8
	12	2	14	10.6	-	24.5	-54.4 <sup>3</sup>	19.9	65.8
9	13	1	15	11.5	-	30.8	47.4	55.8	2.5
	14	2	17	10.1	-	30.3	-51.2 <sup>3</sup>	1.2	32.4

1   <sup>1</sup> To be considered to be significant, inhibition has to be at least 15%

2   <sup>2</sup> Single chain MAb-B43.13, F(ab') MAb-B27.1, and F(ab') M11 were used in the inhibition studies to avoid non-specific inhibition due to the Fc portion of the antibody and cross-reactivity due to HAMA.

5   <sup>3</sup> This experiment produced an anomalous result, as evidenced by the negative number, the reasons for which have yet to be determined.

† Anti-MAb-B43.13 (Ab2) was purified from rabbits injected with MabB43.13.

ND = not determined. NA = not applicable

9

13   Therefore, complex formation can lead to enhanced anti-CA125 as well as anti-idiotypic antibody formation. Manca et al., *J. Immunol.* 140:2893 (1988) and Ling et al., *Immunology* 62:7 (1987) have shown that antibodies can preserve the sequence of their epitope during antigen-processing and antibodies have been used to raise immune responses to less immunogenic epitopes of an antigen.

17   Enhanced antigen-presentation of antigen-antibody complexes was attributed to facilitated antigen uptake via the Fc<sub>γ</sub>-receptor (macrophages, dendritic cells) or membrane-bound Ig (B cells) on professional antigen-presenting cells (APC). The human Fc<sub>γ</sub>RI and RIII-receptor on macrophages and dendritic cells does not bind murine IgG<sub>1</sub>, but the human Fc<sub>γ</sub>RII, which mediates phagocytosis and pinocytosis of small immune complexes, has strong affinity to this murine IgG isotype. Accordingly, various professional APC can be involved in the preferential presentation of the CA125-MAb-B43.13 complex. We tested B cells with two different specificities as well as macrophages as APC: CA125-specific B cells (from mice immunized with CA125) and anti-MAb-B43.13-specific B cells (from mice immunized with MAb-B43.13). Normal B cells served as control. When the proliferation of CA125-specific T cells was monitored by [methyl-<sup>3</sup>H]-Thymidine uptake, optimal stimulation was observed in MAb-B43.13 specific B cells, primed with the CA125-MAb-B43.13 complex (Figure 3), followed by presentation of CA125 by CA125-specific B cells. Enhanced presentation of immune complexes by macrophages and dendritic cells is

1 mediated by preferential uptake via the Fc<sub>Y</sub>R. Figure 4 confirms that CA125 is presented more efficiently by macrophages, if complexed with an antigen specific antibody.

5 The ability of MAb B43.13 to increase the immunogenicity of CA 125 was studied in a mouse model by immunizing a mouse with the CA 125-MAb 43.13 complex, compared to CA125 or MAb B43.13 alone as the immunogen. When the mouse sera was analyzed for anti-CA125 antibody levels, the mice injected with the antigen-antibody complex had the highest titers (see Figure 5). This supports the observation that interaction of the antigen with a specific antibody leads to a higher antigen specific humoral 9 immune response compared to antibody or antigen alone.

13 These results clearly indicate that when an antibody against a single epitope (B43.13) was injected into a patient, an antibody response against the whole antigen is generated which recognizes different epitopes present in the antigen. In other words, injecting a binding agent such as a monoclonal antibody to a soluble multi-epitopic antigen into a patient having a functioning immune system generates an antibody to the antigen, where the generated antibody is inhibited by antibodies to different epitopes.

17 **Example 2.**

21 Similarly, injecting the binding agent to the cancer patients having circulating CA125 lead to antigen specific CTL's. Peripheral Blood Mononuclear Cells (PBMC) from eight patients injected with MAb-B43.13 were tested for cytotoxicity against CA125 positive or CA125 negative ovarian tumor cells in a chromium release assay. The results are shown in Table 5. The specificity of the lysis was confirmed by the ability of MAb-B43.13 to inhibit such lysis, as well as the inability to kill CA125 negative tumor cells. Of the 8 patients who received MAb-B43.13, at least four patients (#5 to #8) were determined 25 to have CA125 specific cytotoxic T lymphocytes (CTL's) in their blood. The generation of CA125 specific CTL's are likely to kill ovarian tumor cells in patients.

1 TABLE 5: Cytotoxicity In Patients Injected With A Vaccine Containing MAb-B43.13

5 PATIENT ID	SAMPLE		PERCENT LYSIS			PERCENT INHIBITION BY MAb-B43.13 (5 μg)	PERCENT DIFFERENCE BETWEEN CA 125 positive and CA 125 negative CELLS
	Injection Number	Days Post Injection	CAOV-4	SK-OV-3	K562		
1	2	17	2.0	0.0	3.7	ND*	insignificant
2	2	0	9.8	7.5	33.5	ND	31
3	3	0	22.8	20.4	64.3	ND	12
4	3	0	25.8	20.2	44.5	4.7	28
5	3	0	65.1	45.4	80.7	ND	43
6	3	0	23.1	20.0	42.0	19.2	16
	3	6	7.4	5.2	10.2	53.0	42
7	4	355	10.3	3.1	18.9	ND	23
8	10	425	25.5	18.2	39.2	15.4	40

29 \*ND = Not Done due to lack of sufficient lymphocytes

Results are the mean of one experiment performed in triplicate

29 **Example 3. Immunotherapy of human ovarian carcinoma in an animal model**

In order to investigate the therapeutic effectiveness, MAb-B43.13 was tested in a human-PBL-SCID/BG mouse model. Mice were reconstituted with human-PBL(normal donors) by i.p. injection of  $2$  to  $3 \times 10^7$  PBL/mouse. MAb-B43.13 was administered at  $100$   $\mu$ g/mouse in PBS, in different experimental set-ups. An isotype matched control antibody (MOPC21 or MAb-170) and PBS injection served as controls. The ovarian cancer cells NIH: OVCAR-Nu3 were injected i.p. at  $1 \times 10^6$  cells/mouse or s.c. at  $4 \times 10^6$  cells/mouse. Hu-PBL-SCID/BG mice were either immunized before injection of tumor cells, or after small tumors were established (two weeks after transplantation). In another experiment, tumor-bearing mice (s.c.) were injected with MAb-B43.13 two weeks after tumor transplantation, along with PBL.

41 Antibody injections were repeated twice in 2-week intervals. Functional and

1 cellular characterization of serum and PBL from these mice demonstrated the successful  
engraftment of a human immune system in those mice.

5 All three experiments showed that MAb-B43.13 treatment could: a) delay or  
prevent development of tumors; b) reduce the size of small, established tumors (s.c. tumor  
injection) or suppress ascites production; c) delay tumor growth when injected prior to  
tumor implantation and d) prolonged the survival of mice (i.p. tumor injection).

Human tumor infiltrating lymphocytes (TIL) were identified in mice using flow  
cytometry, which might contribute to the in vivo anti-tumor activity of MAb-B43.13.

9 At the endpoints of the therapy study, surviving mice from different treatment  
groups were euthanized. Blood, spleen, tumor, and peritoneal washes were obtained from  
the measurement of human immunoglobulin as well as flow cytometric analysis of human  
PBL in mouse tissues. Tumors were also analyzed by immunohistochemistry.

13

**Example 5. Induction of idiotypic network to anti-MUC-1 antibody in breast  
cancer.**

17 MUC-1 proteins (polymorphic epithelial mucin) expressed on malignant epithelium  
are under-glycosylated, which leads to exposure of novel T and B cell epitopes. An anti-  
MUC-1 murine clone can be generated by immunization of mice with CA15.3 antigen, a  
glycoprotein consisting of an MUC-1 protein and carbohydrate residues, and characterized  
for its binding specificity to CA15.3 and MUC-1 tandem repeat core peptide by ELISA and  
21 to MUC-1 transfectoma by FACS analysis. Injection of a monoclonal antibody (Ab1) from  
the anti-MUC-1 murine clone alone and/or conjugated to KLH into mice carrying MUC-1  
transfectoma will result in anti-idiotypic antibody (Ab2) and anti-anti-idiotypic antibody  
(Ab3) production. A minimum of four injections at a dose of 50 µg/mouse would be  
25 expected to obtain a measurable humoral response. The Ab2 and Ab3 levels should reach  
their peak after six injections. The anti-idiotypic antibody (Ab2) would compete with the  
native antigen. CA15.3 T-cell proliferation studies shows specific response to the injected

1 antibody and CA15.3 indicating the presence of idiotype specific T-cells (T2) and anti-idiotype specific T cells (T3). In addition, a breast tumor model was developed using  
5 a human MUC-1 gene transfected mouse mammary carcinoma, 413BCR. Groups of mice can be treated with an anti-MUC-1 antibody conjugated with KLH or human immunoglobulin conjugate, and compared to appropriate positive control (liposomal MUC-1) and negative control (murine immunoglobulin). Immunizations can be performed twice before or after tumor implantation at weekly intervals. The tumor volumes can be measured weekly and the growth rates assessed. A significant tumor reduction would be  
9 observed in mice treated with the anti-MUC-1 antibody conjugate as compared to other groups.

#### Example 6.

13 A composition according to the invention can be produced against CA 19.9 (SLe<sup>a</sup>), an excellent marker for pancreatic cancer (87%), gastric cancer (68%), and colo-rectal cancer (50%).

17 An appropriate binding agent, such as a monoclonal antibody specific for CA 19.9, can be selected. Such an antibody could be an IgG3 antibody that binds strongly to CA 19.9, and is shown to mediate tumor killing through CDC *in vitro*.

21 Approximately 10<sup>4</sup> chromium labeled SW 1116 (2200 CPM) can be incubated with different concentrations of an antibody such as NS1116 and unspecific mIgG3 (20 µg/mL to 0.0025 µg/mL). The antibodies could be incubated for 45 minutes at 4°C. In the treatment groups incubated with HAMA, the antibodies are washed twice with medium and incubated with 1 µg/mL of HAMA for 45 minutes at 4°C. All plates are washed and effector cells (fresh collected human PBLs) or fresh human serum (20% in medium) are  
25 added and incubated for four hours. The cytotoxic index (C.I.) is then calculated. Paired T test is used to analyze each concentration.

It would be expected that the monoclonal antibody specific for CA 19.9 is

1 extremely effective in complement-mediated cytotoxicity. Such cytotoxicity is increased in  
the presence of HAMA. The anti-tumor effect of the MAb can also be analyzed in  
SCID/BG mice reconstituted with human PBL. One would expect to show a reduction in  
tumor volume as a result of the binding agent and the binding agent/antigen complex.

5

**Example 7. PSA directed immunotherapy of prostate cancer (Production of AR47.47)**

9 Prostate specific antigen (PSA) represents an attractive target for the  
immunotherapy of prostate cancer. This glycoprotein is almost exclusively synthesized by  
the prostatic gland and is currently used for the diagnosis and monitoring of prostate cancer  
patients. However, since PSA is recognized as a self-antigen, it is essential for effective  
immunotherapy to develop innovative strategies capable of triggering the immune system  
13 and induce a protective immunity against PSA expressing cells. This example demonstrates  
the use of an antibody to elicit an anti-idiotype cascade associated with an antigen specific  
anti-tumor immune response. A large panel of anti-PSA monoclonal antibodies have been  
produced in our laboratory and these antibodies were evaluated for their potential  
17 therapeutic efficacy against prostate cancer. We have demonstrated that the immunization  
of mice with a selected anti-PSA antibody can induce a specific immunity against PSA  
itself. These results therefore emphasize the potential use of anti-PSA antibodies for the  
immunotherapy of prostate cancer.

21 Hybridoma clones secreting anti-PSA antibodies were produced by fusion of the  
murine myeloma cells Sp2/O with the splenocytes of a Balb/c mouse immunized with  
human PSA. An exemplary clone, AR47.47, binds to an epitope of PSA corresponding to  
amino acid sequences 139-163 of the PSA molecule. It has now been shown that AR 47.47  
25 also recognizes amino acid sequences 135-150, produces a stronger signal, and may be the  
minimum sequences required for binding.

The first criteria of selection used to identify the anti -PSA antibody was the ability

1 of this antibody to interact with circulating PSA. Circulating PSA is found either in a free  
form or complexed to anti-proteases such as  $\alpha$ -anti-chymotrypsin and  $\alpha$ 2-macroglobulin.  
To screen for clones we used three different forms of PSA: free PSA; PSA complexed to  $\alpha$ -  
5 anti-chymotrypsin (PSA-ACT); and free PSA non complexing to  $\alpha$ -anti-chymotrypsin  
(PSA-nc). Free PSA corresponds to PSA directly purified from human seminal fluid. Co-  
incubating free PSA with purified ACT results in the formation of PSA-ACT and PSA-nc.  
PSA-nc can be separated by gel filtration chromatography. It is believed that PSA-nc may  
9 represent the free form of PSA present in the circulation. Complexing of PSA with  $\alpha$ 2-  
macroglobulin results in the total encapsulation of PSA. As a consequence, this form of  
PSA is no longer detectable by monoclonal anti-PSA antibodies. We therefore did not use  
this form of circulating PSA for the screening.

13 PSA belongs to the kallikrein family and a high degree of structural homology is  
found between PSA and the kallikreins HK1 and HK2. The absence of cross reactivity of  
the anti-PSA antibody with kallikrein isolated from human plasma was used as second  
criteria for selection.

17 The hybridoma clone AR47.47 responded to the criteria described above, a strong  
immunoreactivity was observed with the three forms of PSA used for the screening  
whereas no cross reactivity was observed with human plasmatic kallikrein. The hybridoma  
clone AR47.47 was cloned twice by limiting dilution and the second generation clone  
AR47.47R6R6 was chosen for further studies. Clone AR47.47R6R6 was adapted to  
21 standard medium (RPMI 10% FBS) and a cell bank was formed. The absence of  
mycoplasma contamination was verified by using the Boehringer Manheim mycoplasma  
test. Clone AR47.47R6R6 has been deposited in the American Type Culture Collection,  
and has received Accession No. H-B 12526.

25 Immunization in DBA mice with a binding composition according to the invention  
(AR47.47) was examined for the induction of a specific PSA immunity via the idiotypic  
network (i.e. induction of Ab3 antibodies). Anti-PSA antibodies (Ab3) could be detected in  
the serum of animals immunized with AR 47.47, a minimum of two injections of AR 47.47

1 was required for Ab3 production. No reactivity towards PSA was detected for the control groups (mice immunized with an isotype matched control antibody not related to PSA and mice receiving PBS injections).

5 AR 47.47 is directed towards a PSA epitope comprised between the sequence 139-163 of the PSA molecule. The anti-PSA antibodies produced by AR 47.47 immunized mice can specifically interact with the PSA peptide 139-163, showing that at least part of the Ab3 produced are identical in term of specificity to AR 47.47. These results demonstrate that the immunization with AR 47.47 can induce a specific anti-PSA immunity in the host.

9

**Example 8. Anti-idiotypic induction of PSA immunity in mice**

13 Mice were used to determine whether immunization with anti-PSA antibodies can induce a specific immunity against PSA via activation of the idiotypic network. The goal of this experiment was to demonstrate that the immunization of mice with anti-PSA antibodies (Ab1) can stimulate the immune system to generate anti-idiotypic antibodies (Ab2 =surrogate antigen), and anti- anti-idiotypic antibodies (Ab3) capable of reacting with the original antigen.

17 These experiments used a commercially available antibody as a model anti-PSA antibody (RLSD09; ATCC HB-8525). The purified antibody was conjugated to Keyhole Limpet Hemocyanin (KLH) to enhance its immunogenicity. The anti-PSA antibodies conjugated to KLH were still capable of binding to PSA, indicating that the idiotype of the 21 antibodies were not masked by the conjugation procedure. B43.13 antibody, a mouse monoclonal antibody of the same isotype as the PSA antibody (IgG1) was used as the control. B43.13 antibody is specifically directed against the CA125 ovarian tumor antigen and does not cross react with PSA. In addition FACS analysis verified that the B43.13 antibody does not bind at the cell surface of Line-1-PSA or P81 5-PSA.

25 Mice were subdivided into three groups of five mice each. The first group of mice was immunized with anti-PSA antibody conjugated to KLH. The second group of mice

1 was immunized with the control B43.13 antibody conjugated to KLH. The third group of mice received PBS injection. Injections were performed i.p. at 10 days intervals with complete Freund adjuvant for the first injection and incomplete Freund adjuvant for the second injection.

5 Ab2 is a surrogate antigen capable of mimicking the PSA epitope recognized by the injected anti-PSA antibody. A competitive inhibition assay was established to measure the serum level of Ab2. This assay was performed 5 days after the second injection. An inhibition was observed after incubation in the presence of mouse sera from mice  
9 immunized with anti-PSA antibody, but not when sera from mice immunized with control antibody or PBS were used. These results indicate that the immunization of Balb/c mice and DBA mice with the anti-PSA antibody can induce the formation of anti-idiotypic antibody (Ab2) capable of mimicking PSA.

13

**Example 9. Effect of Anti-PSA immunization on tumor development**

Balb/c mice were used to determine whether immunization with anti-PSA antibodies can protect the animals against a subsequent tumor challenge. Balb/c mice were  
17 divided into 3 groups of 5 mice each. The first group was immunized with anti-PSA antibody RLSD09 conjugated to KLH, the second group was immunized with control antibody B43 conjugated with KLH, the third group received PBS injections. A total of 4 injections were given for each group using 50 µg of antibodies for each injection. The  
21 tumor cells Line-1-PSA were injected intravenously between the third and fourth injections. Nineteen days after tumor inoculation, the mice were sacrificed, the number of tumor foci in the lungs and Ab3 levels in the serum were determined.

The tumor burden in the group of mice immunized with anti-PSA MAb was  
25 considerably lower compared to the group of mice immunized with control antibody. Of particular interest is the demonstration, in the group of mice immunized with anti-PSA MAb, of a negative correlation between Ab3 levels and the number of tumor foci in the

1      lungs.

**Example 10. Anti-inflammatory composition.**

5      To test for the effectiveness of a composition containing a binding agent in treating  
inflammation, a double blind experiment can be performed on 18 Sprague Dawley rats  
(weight about 450g) divided into 3 groups (8 rats in each group).

9      The first group can be vaccinated with KLH conjugated IgM antibody specific for a  
carbohydrate ligand on leukocytes (250 µg/rat, i.p.). The second group is vaccinated with  
KLH conjugated IgM antibody with no binding to the same ligand (250 µg/rat, i.p.). The  
third group is a control group, and would receive no vaccination.

13     Inflammation can be induced by injecting 1% carrageenan in 0.9% NaCL (type IV),  
in the rat right hind paw (0.5 ml/rat). Paw edema can be observed by water displacement  
measurement and caliper measurement.

The inhibitory effect of this monoclonal antibody on inflammation is clinically  
different from the control group and control IgM antibody group.

17     **Example 11. Photoactivation increases immunogenicity**

Normal, healthy, Sprague-Dawley rats were used. Animals were randomly grouped  
(4 per group) to receive four different doses (5 µg, 10 µg, 25 µg and 50 µg) of MAb 43.13.  
Pre-injection blood samples were drawn prior to initiation of the injection schedule. Each  
21     rat received the appropriate dose of MAb diluted in sterile 0.01 M phosphate buffered saline  
intravenously. A second study group received 20 µg of each MAb preparation with or  
without Incomplete Freund's Adjuvant (IFA). Blood samples were taken just prior to the  
dose injection at 0, 21, 42, 63 and 77 days.

25     MAb-B43.13 is a murine IgG, reactive with CA 125. Antibody preparations  
consisted of MAb-B43.13 in the native form or in a UV-exposed form (e.g., photoactivated).

1 Native MAb was diluted from a stock concentration of 5 mg/mL with 0.01 M phosphate buffered saline to doses of 5,10, 25 and 50  $\mu$ g/100  $\mu$ L. UV exposed MAb was reconstituted from the lyophilized form with 0.01 M phosphate buffered saline (2.2 mg/0.47 mL) and diluted to obtain the same doses as for the native MAb.

5 An assay was developed to measure the rat anti-mouse response in the serum of the injected animals. Anti-isotype rat anti-mouse antibodies were measured using an ELISA plate coated with an isotype matched control antibody, MOPC 21. Samples were diluted 1/100, allowed to react with the coated antibody, washed, and bound antibody detected

9 using peroxidase conjugated goat anti-rat IgG (H + L) with ABTS substrate. Unknowns were read off a standard curve generated using a commercial rat anti-mouse antibody.

13 The results of the rat anti-mouse (RTAMA) analysis of sera from the various groups of rats injected with native and UV exposed MAb-B43.13 are shown in Tables 6 and Table 7. The immunological response to the preparations is expressed in terms of the number of responders in each group, with the numerical cut-off defined in the tables. This value (mean of all pre-injection samples (blanks) + 3 S.D.) ensures that a true positive response is measured and the results are unlikely to be due to assay variation. The tabulation of

17 responders is probably more meaningful given that the fluctuation of the magnitude of response can be very large and therefore, hinder interpretation.

21

25

1

Table 6

## ANIMAL RESPONSE\* TO INTRAVENOUS INJECTION OF NATIVE AND UV EXPOSED MAb-B43.13 PREPARATIONS

Sampling Time	Preparation	Number of Responders			
		5 µg	10 µg	25 µg	50 µg
5 Pre-injection (blank)	Native	NA**	NA	NA	NA
	UV exposed	NA	NA	NA	NA
9 Day 21	Native	0	0	0	0
	UV exposed	2	3	1	1
13 Day 42	Native	0	1	0	1
	UV exposed	2	3	4	3
17 Day 63	Native	1	3	3	3
	UV exposed	2	4	3	4
21 Day 77	Native	2	2	2	1
	UV exposed	3	4	4	4

\* Number of animals responding in a group of four (RTAMA values  $\geq$  pre-injection sample mean + 3 S.D.)

13

\*\* NA = Not Applicable

17

The data tends to confirm that the response to the UV exposed MAb-B43.13 occurs earlier (after only one injection) as shown by the greater number of responders at all dose levels in the Day 21 groups.

21

Furthermore, at all other time periods (and after multiple injections), the proportional response of each group given intravenous UV exposed MAb-B43.13 is greater. It may be suggested that the response is sustained longer for UV exposed MAb-B43.13 since the native MAb-B43.13 appears to show a reduced response rate from Day 23 to Day 77. Actual values of increased response at day 77 are shown in Table 7.

1

Table 7

**TOTAL AND AB<sub>2</sub> INDUCTION IN RATS INJECTED WITH NATIVE OR UV-EXPOSED MAB--B43.13**

5

	TOTAL IMMUNE RESPONSE (mean $\pm$ S-E)	Ab <sub>2</sub> RESPONSE (mean $\pm$ S-E)
Native Mab — B43.13	38.47 $\pm$ 2.99*	18.77 $\pm$ 8.23
UV-exposed Mab — B43.13	1608.67 $\pm$ 369.39*	87.27 $\pm$ 45.11

9

n = 3

\* p = 0.0496

**Example 12. Protein modification as a result of UV exposure**

The final chemical species present after photoactivation are specific for a given set of exposure conditions and the composition of the matrix solution (as described above). For simple polypeptides containing any of the three primary UV absorbing (UV-B) amino acids (cystine, tryptophan, tyrosine) the consequences of UV exposure can lead to amide bond cleavage, disulfide bond cleavage, alteration of absorbing amino acids and alteration of adjacent or close proximity amino acids. These changes are brought about by direct photoionization or photoexcitation and indirectly by radical formation from other constituents. The nature and extent of these modifications is highly dependent on the chemical reactivities of the species generated and other constituents reactive tendencies or stabilizing/quenching capabilities. For this size of molecule any alteration generally results in dramatic changes in biological function.

These same reactions can take place in larger proteins, however secondary and tertiary structural elements present differing substrates for UV exposure in spite of similar amino acid sequences. Therefore, the hydrophobic/hydrophilic nature and proximal amino acids from distant chain sequences as a result of folding alter the micro-environment

1 and therefore influence the degree and nature of the modification, in addition to other constituents issues stated above. Given the predominance of the tryptophan absorption profile in this UV band width, it is thought to be the primary site of the initial photoactivation process, but direct action on cysteine and tyrosine are also viable.

5 The mechanism for indirect amino acid modifications has been proposed as local hydrated electron generation or direct energy transfer from the primary absorbing site. The primary observed changes for large proteins focus on measurable chemical/biochemical changes such as absorption and fluorescence determinations of  
9 aromatic amino acids which relate to global modifications. Individual amino acid alterations be detected in this group of proteins where sulphydryl content can be determined as evidence of cysteine disulfide cleavage and/or where a critical amino acid for function is involved. For smaller proteins amino acid hydrolysis and complete  
13 quantitation can be performed. The primary concern for functional large proteins, such as enzymes, receptor, or antibodies, is therefore not specific amino acid modification but the consequences of any change on their biological function, and has invariably been described as loss of enzyme function, receptor recognition, or antigen binding.

17

**Example 13. UV Exposed B43-13/CA125 antibody/antigen complex Produces Better CA125 Specific Cellular immune Response and better humoral response.**

21 Better cellular immune response was observed when the UV exposed antibody was presented in association with the antigen to T-cells. Thus, macrophages isolated from mouse peritoneal cavities were stimulated with native B43.13 or UV exposed B43.13 in association with CA125 and presented to CA125 specific mouse T-cells isolated from mice  
25 injected with CA125. Control experiments included stimulation of the macrophages without the antigen. When the proliferation of T-cells as monitored by [<sup>3</sup>H] - thymidine uptake was followed, optimal stimulation index was observed in macrophages stimulated with UV exposed B43.13 - CA125 complex. The results are summarized in Table 8 below.

1

Table 8

5

STIMULATING AGENT <sup>1</sup>	STIMULATION INDEX <sup>2</sup>
CA125	2.76
Native MAb — B43.13	3.98
UV-exposed MAb — B43.13	3.31
Native MAb — B43.13 — CA125	4.71
UV-exposed MAb — B43.13 — CA125	5.28

9

1. 1  $\mu$ g/ml of the antibody and 100 Units/ml CA125 were used.  
 13 2. Mean of three individual experiments done in triplicate.

Example 14.

17 Three derivatives of scFv with additional C-terminal extensions containing mouse  
 and human tuftsin (pDL-6 and pDL-11), or a control sequence (pDL-10), were designed. To  
 construct plasmids pDL-6, pDL-10, and pDL-11, DNA oligodeoxyribonucleotides  
 (5'-GAATTCTGGAGGTGGTACCCAGCCTAGGTAGC-3',  
 21 5'-GAATTCTGGAGGTGGTGGATGTGC-3', and  
 5'-GAATTCTGGAGGTGGTACCAAGCCTAGGTAGC-3')  
 coding for the amino acid sequences N-SerGlyGlyGlyThrGlnProArg-C,  
 N-SerAlaGlyGlyGlyCysAla-C, and N-SerGlyGlyGlyThrLysProArg-C, were used by  
 25 inserting fragments in *Eco*RI and *Eag*I sites of pPIC-B43. The plasmid DNAs were  
 transformed into competent GS115 cells by electroporation and the resulting transformants

1        were selected on histidine-deficient media. All positive clones obtained were isolated, cultured in induction media, and analyzed for protein expression in SD S-PAGE followed by Commassie staining. The scFv-tuftsins proteins were produced in minimal media to simplify some downstream protein purification process.

5        In order to evaluate the anti-idiotypic response, six to 8-week-old BALB/c mice were immunized with 50 $\mu$ g scFv-tuftsins subcutaneously (Day 0). Two weeks later the mice were received 25 $\mu$ g of scFv-tuftsins intraperitonealy. The serum of mice was collected on Day 7, 14 and 21.

9        The anti-idiotypic antibody production was detected by enzyme-linked immunosorbent assay (ELISA). Briefly, chimeric B43.13 was coated to a solid surface and then blocked by 3% BSA/PBS. The chimeric B43. 13 was incubated with serum samples for 1 h and then incubated with goat anti-mouse H + L-HRPO for another hour, followed by 13 three washes with Tween 20/PBS. A color reaction was developed by adding 50 $\mu$ l of substrate solution. Absorbence was read at 405nm. The same procedure was applied to detect anti-anti-idiotypic antibody (Ab3) production except CA125 was coated to ELISA plate at the beginning.

17       The data shows that it is possible to detect both Ab2 and Ab3 in the serum samples and this indicates that scFv-tuftsins retained the idiotypic immunogenicity which could trigger humoral immune response in mice. We found that the mice immunized with scFv-tuftsins started to show strong anti-idiotypic antibody (Ab2) production after day 20 post the first immunization. However, the anti-anti-idiotypic antibody (Ab3) production appeared earlier, peaking around day 15. This indicates that the induction of an idiotypic network response might be an important part of the effector mechanism in MAb-based therapy.

25

**Example 15. Construction and characterization of single chain antibody**

The MAb B43.13 variable domain sequences were PCR-amplified using sequence

1 specific primers, and engineered into a cloning vector with scFv orientation of V1-linker-  
Vh. The DNA fragment coding for the scFv was then sub-cloned into *P. pastoris* vector,  
pPIC-9 with aF secretion signals, resulting in recombinant plasmid pPIC-B43.13. One  
5 derivative of pPIC-B43.13 with additional C-terminal extensions containing one cysteine  
(pDL10) was designed to form a disulfide bridge. Therefore, the antigen binding activity  
can be enhanced by increase of avidity. To construct plasmids pDL10, DNA  
oligodeoxyribonucleotides (5'-GAATTCTGGAGGTGGATGTGC-3') coding  
for the amino acid sequences, N-SerAlaGlyGlyGlyCysAla-C were used by inserting  
9 fragments in *Eco*RI and *Eag*I sites of pPIC-B43.13.

The plasmid DNAs were transformed into competent GS115 cells by  
electroporation and the resulting transformants were selected on histidine-deficient media.  
After screening for integration at the correct loci, (i.e. colonies can grow on a -  
13 his/ + glycerol plate but grow slowly on a -his/ + methanol plate), all positive clones  
obtained were isolated, cultured in induction media, and analyzed for protein expression in  
SDS-PAGE followed by Coomassie staining, as we described previously (Luo et al., 1997).  
The protein samples were dialysed against PBS and concentrated using Centricon 10 filter  
17 (Amicon, Danvers, MA).

Purity of scFv-pDL10 were analyzed by SDS-PAGE under reducing condition.  
CA125-binding specificity was determined using a ELISA in which microtiter plate wells  
were coated with CA125, CA15.3 ( a human breast cancer antigen), or CA19.9 (a human  
21 colon cancer antigen). The bound single chain antibody was detected by peroxidase-labeled  
goat ant-mouse H and L (Southern Bio. Assoc.) For 1 hour at room temperature.  
Following three washes, 50 $\mu$ l of ABTS substrate solution was added. The absorbance was  
measured at 405nm.

25 Single chain Fv containing poly(lactic-co-glycolic acid) microspheres were prepared  
by a double-emulsion technique with some modifications (Uchida et al., 1994). Na<sup>125</sup>I  
labeled scFv-pDL10 was used as a tracer to determine the loading efficiency. Briefly, scFv-  
pDL10 (1.5 mg) and Na<sup>125</sup>I-scFv-pDL10 (0.4  $\mu$ g) in PBS was mixed with 500  $\mu$ l of

1 chloroform containing 100 mg PLGA 50/50 (Lactel). The mixture was sonicated for 15 s  
using a sonicator homogenizer (Heat System, New York). The resulting emulsion was  
added to 2 ml of 9% poly(vinyl alcohol) (PVA, Aldrich, USA). Emulsification was  
continued by sonicate on for 1 min. The emulsion was transferred to 8 ml of 9% PVA and  
5 stirred for 2 hours for evaporation of the chloroform. Microspheres were recovered by  
centrifugation (15 min, 15000 rpm) and have washed with distilled water and freeze dried  
for at least 24 hours.

9 BALB/c female mice 6-8 weeks of age were used in all in vivo experiments. The  
immunization groups included five groups: 1) immunized with PLGA microspheres, 2)  
immunized with scFv-pDL10, 3) immunized with scFv-pDL10 formulated in PLGA  
microspheres, and the other two groups immunized with the mixture of formulated scFv-  
pDL10 and GM-CSF or TNF- $\alpha$ . After collection of pre-immune serum samples, groups of 4  
13 mice received two subcutaneous immunizations on day 0 and day 14, followed by two  
intraperitoneal immunizations on day 21 and day 28. The dose for immunization was 10  
mg of the microspheres for s.c., 5 mg for i.p.. For the other groups that received no  
microspheres, the dose of scFv-pDL10 matched the amount formulated. The cytokines  
17 were purchased from R & D Systems (USA) and were given to mice at a dose of 0.1  $\mu$ g per  
day. Tail vein blood samples were taken periodically into Microtainer tubes (Becton  
Dickinson, USA) and frozen at -80°C until assay.

21 **Example 16 . Dose**

Those with skill in the art recognize that the administered dosage can vary widely  
based on a wide set of different circumstances. The following provides preliminary dosage  
guidelines.

25 Retrospective analysis of more than 100 patients who have been injected up to ten  
times with a 2mg dose of MAb-B43.13 indicated that some of these patients experienced: a)  
an unusual course of their disease, characterized by unexpectedly long survival times; and

1       b) no significant adverse reaction or toxicity.

5       Immunological studies were conducted to understand and evaluate the *in vivo* mechanism of action of MAb-B43.13. These studies indicated that the extent of anti-idiotypic induction in patients injected with a 2mg dose of MAb-B43.13 was unrelated to the number of injections or the clinical stage of their disease. However, anti-idiotypic induction is dependent on the levels of the circulating CA 125 present in the patient's sera. Additional experiments demonstrated that the injection of MAb-B43.13 into patients with measurable serum CA 125 led to the formation of antigen-antibody complexes, resulting in 9 antigen epitope presentation and antigen-specific humoral and cellular response to the tumor.

13      These studies indicate that an effective dose requires only enough antibody to optimally deliver and present all possible circulating CA 125 antigen to the immune system. *In vitro* studies indicated that 1 ng of MAb-B43.13 can bind 10 units of CA 125. Assuming 40 mL of plasma per kg of body weight, the injection of 2 mg of MAb-B43.13 into a 60 kg patient can bind approximately 8333 U/mL of CA 125 in serum. Since all of the ovarian cancer patients tested to date have had far less than 8333 U/mL of CA 125 in 17 their serum, an injection of 2 mg of MAb-B43.13 is more than sufficient to induce the required immune response. Additionally, in patients that received radiolabeled MAB-B43.13 for immunoscintographic confirmation of the disease, the results of imaging were excellent in spite of high serum CA 125, suggesting that there is excess MAB-B43.13 for 21 specific tumor uptake.

Furthermore, multiple injections at selected intervals appear to provide optimal benefits to patients, since CA 125 is generated throughout the course of the disease.

25      Finally, the retrospective analysis showed that the 2 mg dose appears to have therapeutic efficacy; none of the patients (> 100) have developed any serious side effects or adverse reactions. If the total HAMA response is an indication of anti-idiotypic induction, a 2 mg dose generates significant levels of anti-idiotypic antibodies to produce the desired therapeutic benefit. Multiple injections of 2 mg of MAb-B43.13 at selected intervals appears

1 to maintain the anti-idiotypic antibodies at the desired therapeutic level without causing any isotypic HAMA-induced toxicity.

A range of effective doses or a therapeutically acceptable amount of MAb-B43.13 therefore includes, but is not limited to, 2 mg or less.

5

While the present invention has been described in some detail by way of illustration and example, it should be understood that the invention is susceptible to various modifications and alternative forms, and is not restricted to the specific embodiments set forth. It should be understood that these specific embodiments are not intended to limit the invention, and the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.

1 We claim:

1. A method for inducing a host immune response against a multi-epitopic *in vivo* antigen, other than a tumor associated antigen, present in the host's serum, which antigen does not elicit a host immune response, the method comprising contacting the antigen with  
5 a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair wherein a host immune response is elicited against a second epitope on the antigen.

9 2. A method for inducing the production of an immune response against a multi-epitopic *in vivo* tumor associated antigen, other than a CA125, CA19.9 and CA15.3, present in a host's serum, the method comprising contacting the antigen with a  
13 composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair wherein a host immune response is elicited against a second epitope on the antigen.

17 3. A method for inducing an immune response against a cellular antigen that does not elicit a host immune response, the method comprising administering to the host a binding agent that binds an epitope of a soluble form of the antigen in an amount of binding agent between  $0.1\mu\text{g}$  and 2 mg per kg of body weight of the host.

21 4. A method for inducing an immune response against a cellular antigen that does not elicit a host immune response, the method comprising intravenously administering to the host a binding agent that binds an epitope of a soluble form of the antigen.

25 5. The method according to any of claims 1-4, wherein the host immune response comprises a cellular and humoral immune response.

- 1        6.        The method according to any of claims 1-4, wherein the host immune response  
comprises a cellular response.
- 5        7.        The method according to any of claims 1-4, wherein the host immune response  
comprises a humoral response.
- 9        8.        The method according to any of claims 1-4, wherein the antigen is a soluble antigen.
- 13       9.        The method according to any of claims 1-4, wherein the binding agent is an  
antibody.
- 17       10.       The method according to claim 9, wherein the antibody is a murine monoclonal  
antibody.
- 17       11.       The method according to claim 10, wherein the antibody does not induce isotypic  
induced HAMA toxicity in the host.
- 21       12.       The method according to claim 8, wherein the antigen is associated with a human  
disease or pathological condition.
- 25       13.       The method according to claim 12, wherein the disease or pathological condition is  
cancer.
- 25       14.       A therapeutic composition comprising a binding agent specific for a first epitope on  
a multi-epitopic *in vivo* antigen, other than a tumor associated antigen, present in the host's

1 serum, wherein the binding agent specifically binds to a first epitope on the antigen and forms a binding agent/antigen pair wherein a host immune response is elicited against a second epitope on the antigen.

5 15. A therapeutic composition comprising a binding agent specific for a first epitope on a multi-epitopic *in vivo* tumor associated antigen, other than a CA125, CA19.9 and CA15.3, present in a host's serum, which antigen does not elicit a host immune response, wherein the binding agent specifically binds to a first epitope on the antigen and forms a binding agent/antigen pair wherein a host immune response is elicited against a second epitope on the antigen.

9

16. A therapeutic composition comprising a binding agent specific for an epitope of a cellular antigen which does not elicit a host immune response, in an amount sufficient to administer binding agent at a concentration between 0.1 $\mu$ g and 2 mg per kg of body weight of the host, wherein the binding agent binds to an epitope of a soluble form of the antigen and induces an immune response against the antigen.

13

17. A therapeutic composition for intravenous administration comprising a binding agent that binds an epitope of a soluble form of a cellular antigen which does not elicit a host immune response, wherein the binding agent specifically binds to the epitope and induces an immune response against the antigen.

21

18. The therapeutic composition according to any of claims 14-17, wherein the host immune response comprises a cellular and humoral immune response.

25

19. The therapeutic composition according to any of claims 14-17, wherein the host immune response comprises a cellular response.

1        20.    The therapeutic composition according to any of claims 14-17, wherein the host  
immune response comprises a humoral response.

5        21.    The therapeutic composition according to any of claims 14-17, wherein the antigen  
is a soluble antigen.

22.    The therapeutic composition according to any of claims 14-17, wherein the binding  
agent is an antibody.

9        23.    The therapeutic composition according to claim 22, wherein the antibody is a  
murine monoclonal antibody.

13      24.    The therapeutic composition according to claim 23, wherein the antibody does not  
induce HAMA in the host.

17      25.    The therapeutic composition according to claim 21, wherein the antigen is  
associated with a human disease or pathological condition.

21      26.    The therapeutic composition according to claim 25, wherein the disease or  
pathological condition is cancer.

25      27.    The method according to any of claims 1-4, wherein the binding agent is  
photoactivated.

28.    The method according to claim 7, wherein the humoral response comprises anti-  
idiotype antibodies.

1        29.    The method according to claim 3, wherein the amount of binding agent is between  
1  $\mu$ g and 200  $\mu$ g per kg of body weight of the host.

5        30.    A method for inducing an immune response comprising determining that a high  
level of pre-determined antigen is present in a patient, and administering a composition  
comprising a binding agent according to the invention.

9        31.    A method for inducing a host immune response against a pre-determined antigen  
present in a host's serum, which antigen does not elicit a host immune response, the  
method comprising contacting the antigen with a composition comprising a binding agent  
that specifically binds to the antigen and allowing the binding agent to form a binding  
agent/antigen pair wherein a beneficial host immune response is elicited against the  
13      antigen.

17      32.    The method of claims 1 to 4 wherein the immune response is a beneficial immune  
response.

17      33.    The composition of claims 14-17 wherein the immune response is a beneficial  
immune response.





Figure 1

Figure 2






Figure 3




Figure 4




Figure 5




Figure 6

Percentage of Inhibiting Samples



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :  A61K 39/00, 39/395, 41/00		A3	(11) International Publication Number: <b>WO 99/65517</b>  (43) International Publication Date: 23 December 1999 (23.12.99)															
<p>(21) International Application Number: PCT/IB99/01114</p> <p>(22) International Filing Date: 15 June 1999 (15.06.99)</p> <p>(30) Priority Data: 09/094,598 15 June 1998 (15.06.98) US 09/152,698 2 September 1998 (02.09.98) US</p> <p>(71) Applicant (for all designated States except US): ALTAREX CORP. [CA/CA]; Campus Tower, Suite 300, 8625-112 Street, Edmonton, Alberta T6G 2E1 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): MADIYALAKAN, Ragupathy [CA/CA]; 9741-89 Avenue, Edmonton, Alberta T6E 2S1 (CA). SCHULTES, Birgit [CA/CA]; 529 Hegler Crescent, Edmonton, Alberta T6R 1T4 (CA). BAUM, Richard, P. [DE/DE]; Bergweg 4, D-55595 Hargesheim (DE). NOUJAIM, Antoine, A. [CA/CA]; 58 Wilkins Road, Edmonton, Alberta T6M 2K4 (CA). LEVEUGLE, Beatrice [CA/CA]; 9741-89 Avenue, Edmonton, Alberta T6E 2S1 (CA). KREUTZ, Fernando, T. [BR/BR]; Apt. 72, Rua Felipe Camarao, 147, CEP-90035-141 Porto Alegre, RS (BR).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> <p>(88) Date of publication of the international search report: 3 February 2000 (03.02.00)</p>																
<p>(54) Title: THERAPEUTIC COMPOSITIONS THAT PRODUCE AN IMMUNE RESPONSE BY ALTERING THE ANTIGEN</p> <table border="1"> <thead> <tr> <th>Inhibitor</th> <th>Black Segment (%)</th> <th>White Segment (%)</th> </tr> </thead> <tbody> <tr> <td>CA125</td> <td>26</td> <td>2</td> </tr> <tr> <td>B43.13 scFv</td> <td>22</td> <td>6</td> </tr> <tr> <td>B27.1 F(ab')</td> <td>11</td> <td>17</td> </tr> <tr> <td>M11 F(ab')</td> <td>8</td> <td>11</td> </tr> </tbody> </table>				Inhibitor	Black Segment (%)	White Segment (%)	CA125	26	2	B43.13 scFv	22	6	B27.1 F(ab')	11	17	M11 F(ab')	8	11
Inhibitor	Black Segment (%)	White Segment (%)																
CA125	26	2																
B43.13 scFv	22	6																
B27.1 F(ab')	11	17																
M11 F(ab')	8	11																
<p>(57) Abstract</p> <p>The invention concerns methods and compositions for stimulating a host's immune response, particularly for the treatment of cancer. The methods and compositions according to the invention use binding agents such as antibodies to generate an immune response to a predetermined soluble antigen. In accordance with the invention, the binding agent-soluble antigen complex alters the immunogenic condition of the host by generating new immunogens that are recognizable by the immune system. This leads to a humoral and/or cellular immune response.</p>																		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB 99/01114

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K39/00 A61K39/395 A61K41/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MADIYALAKAN R ET AL: "ANTIIDIOTYPE INDUCTION THERAPY: EVIDENCE FOR THE INDUCTION OF IMMUNE RESPONSE THROUGH THE IDIOTYPE NETWORK IN PATIENTS WITH OVARIAN CANCER AFTER ADMINISTRATION OF ANTI-CA125 MURINE MONOCLONAL ANTIBODY B43.13" HYBRIDOMA, US, NEW YORK, NY, vol. 14, no. 2, 1995, page 199-203 XP002913336 abstract page 202, left-hand column, paragraph 3 -right-hand column, paragraph 1 page 203, left-hand column, paragraph 2 ----</p> <p style="text-align: right;">-/-</p>	1-26, 28-33

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

30 November 1999

Date of mailing of the international search report

15/12/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Covone, M

**INTERNATIONAL SEARCH REPORT**

Inte... nat Application No

PCT/IB 99/01114

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LEVEUGLE, B. (1) ET AL: "PSA-directed immunotherapy of prostate cancer." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 355. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN, XP002124369 the whole document ---	1-26, 28-33
X	FOON K A ET AL: "Clinical and immune responses in advanced colorectal cancer patients treated with anti - idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen." CLINICAL CANCER RESEARCH, (1997 AUG) 3 (8) 1267-76. , XP002124370 abstract page 1268, left-hand column, paragraph 3 page 1271, right-hand column, paragraph 3 -page 1272, left-hand column, paragraph 1 ---	1-26, 28-33
X	DATABASE CANCERLIT 'Online! UEMURA H ET AL: "Generation of anti - idiotype antibodies related to prostatic specific antigen (Meeting abstract)." retrieved from STN Database accession no. 97614137 XP002124371 abstract & JPN J CANCER RES, (1995). VOL. 7, NO. 10, PP. 427. ISSN: 0546-0476., Dept. of Urol., Nara Med. Univ. ---	1-26, 28-33
A	WO 95 04548 A (JENNER TECHNOLOGIES) 16 February 1995 (1995-02-16) page 1, line 3-10 claims ---	1-33
P, X	SCHULTES B C ET AL: "Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)." CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1998 JUN) 46 (4) 201-12. , XP000857366 abstract page 202, left-hand column, paragraph 4 page 210, left-hand column, paragraph 6 -right-hand column, paragraph 1 page 210, right-hand column, paragraph 4 -page 211, left-hand column, paragraph 1 ---	1-33

## INTERNATIONAL SEARCH REPORT

Inte:  nal Application No

PCT/IB 99/01114

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X, L	WO 98 57661 A (NOUJAIM ANTOINE A ; SYKES THOMAS R (CA); BAUM RICHARD P (DE); MADIY) 23 December 1998 (1998-12-23) page 9, line 22-27 page 11, line 21 -page 12, line 14 table 2 examples 1,3,6 -----	1-33

**INTERNATIONAL SEARCH REPORT**

Ir. National application No.

PCT/IB 99/01114

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 1-13, 28-33  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
see FURTHER INFORMATION sheet PCT/ISA/210
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-13,28-33 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Continuation of Box I.1

Claims Nos.: 1-13 28-33

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/01114

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9504548	A 16-02-1995	AU	686660 B	12-02-1998
		AU	7631294 A	28-02-1995
		CA	2168952 A	16-02-1995
		EP	0721345 A	17-07-1996
		JP	9504000 T	22-04-1997
		US	5925362 A	20-07-1999
WO 9857661	A 23-12-1998	AU	8143998 A	04-01-1999

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**